WO2006066126A2 - Phenol-heterocyclic ligands, metal complexes, and their uses as catalysts - Google Patents

Phenol-heterocyclic ligands, metal complexes, and their uses as catalysts Download PDF

Info

Publication number
WO2006066126A2
WO2006066126A2 PCT/US2005/045766 US2005045766W WO2006066126A2 WO 2006066126 A2 WO2006066126 A2 WO 2006066126A2 US 2005045766 W US2005045766 W US 2005045766W WO 2006066126 A2 WO2006066126 A2 WO 2006066126A2
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
group
ligand
aryl
formula
Prior art date
Application number
PCT/US2005/045766
Other languages
English (en)
French (fr)
Other versions
WO2006066126A3 (en
Inventor
Margarete K. Leclerc
Xiahong Bei
James Longmire
Gary M. Diamond
James A. W. Shoemaker
Anne M. Lapointe
Lily Ackerman
Original Assignee
Symyx Technologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symyx Technologies, Inc. filed Critical Symyx Technologies, Inc.
Publication of WO2006066126A2 publication Critical patent/WO2006066126A2/en
Publication of WO2006066126A3 publication Critical patent/WO2006066126A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/003—Compounds containing elements of Groups 4 or 14 of the Periodic System without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F10/00—Homopolymers and copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F12/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
    • C08F12/02—Monomers containing only one unsaturated aliphatic radical
    • C08F12/04—Monomers containing only one unsaturated aliphatic radical containing one ring
    • C08F12/06—Hydrocarbons
    • C08F12/08—Styrene
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F110/00—Homopolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond
    • C08F110/04—Monomers containing three or four carbon atoms
    • C08F110/06—Propene
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F110/00—Homopolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond
    • C08F110/14—Monomers containing five or more carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F210/00—Copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond
    • C08F210/16—Copolymers of ethene with alpha-alkenes, e.g. EP rubbers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F4/00—Polymerisation catalysts
    • C08F4/42—Metals; Metal hydrides; Metallo-organic compounds; Use thereof as catalyst precursors
    • C08F4/44—Metals; Metal hydrides; Metallo-organic compounds; Use thereof as catalyst precursors selected from light metals, zinc, cadmium, mercury, copper, silver, gold, boron, gallium, indium, thallium, rare earths or actinides
    • C08F4/60—Metals; Metal hydrides; Metallo-organic compounds; Use thereof as catalyst precursors selected from light metals, zinc, cadmium, mercury, copper, silver, gold, boron, gallium, indium, thallium, rare earths or actinides together with refractory metals, iron group metals, platinum group metals, manganese, rhenium technetium or compounds thereof
    • C08F4/62—Refractory metals or compounds thereof
    • C08F4/64—Titanium, zirconium, hafnium or compounds thereof
    • C08F4/659—Component covered by group C08F4/64 containing a transition metal-carbon bond
    • C08F4/65908—Component covered by group C08F4/64 containing a transition metal-carbon bond in combination with an ionising compound other than alumoxane, e.g. (C6F5)4B-X+
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F4/00—Polymerisation catalysts
    • C08F4/42—Metals; Metal hydrides; Metallo-organic compounds; Use thereof as catalyst precursors
    • C08F4/44—Metals; Metal hydrides; Metallo-organic compounds; Use thereof as catalyst precursors selected from light metals, zinc, cadmium, mercury, copper, silver, gold, boron, gallium, indium, thallium, rare earths or actinides
    • C08F4/60—Metals; Metal hydrides; Metallo-organic compounds; Use thereof as catalyst precursors selected from light metals, zinc, cadmium, mercury, copper, silver, gold, boron, gallium, indium, thallium, rare earths or actinides together with refractory metals, iron group metals, platinum group metals, manganese, rhenium technetium or compounds thereof
    • C08F4/62—Refractory metals or compounds thereof
    • C08F4/64—Titanium, zirconium, hafnium or compounds thereof
    • C08F4/659—Component covered by group C08F4/64 containing a transition metal-carbon bond
    • C08F4/65912—Component covered by group C08F4/64 containing a transition metal-carbon bond in combination with an organoaluminium compound

Definitions

  • the present invention relates to ligands, ligand-metal compositions, complexes, and catalysts useful in the polymerization of olefins and other transformations.
  • Ancillary (or spectator) ligand-metal coordination complexes are useful as catalysts, additives, stoichiometric reagents, solid-state precursors, therapeutic reagents and drugs.
  • Ancillary ligand-metal coordination complexes of this type can be prepared by combining an ancillary ligand with a suitable metal compound or metal precursor in a suitable solvent at a suitable temperature.
  • the ancillary ligand contains functional groups that bind to the metal center(s), remain associated with the metal center(s), and therefore provide an opportunity to modify the steric, electronic and chemical properties of the active metal center(s) of the complex.
  • Certain known ancillary ligand-metal complexes and compositions are catalysts for reactions such as oxidation, reduction, hydrogenation, hydrosilylation, hydrocyanation, hydroformylation, polymerization, carbonylation, isomerization, metathesis, carbon-hydrogen activation, carbon-halogen activation, cross-coupling, Friedel-Crafts acylation and alkylation, hydration, Diels-Alder reactions and other transformations.
  • ancillary ligand-metal complexes and compositions are in the field of polymerization catalysis.
  • the ancillary ligand typically offers opportunities to modify the electronic and/or steric environment surrounding an active metal center. This allows the ancillary ligand to assist in the creation of possibly different polymers.
  • Group 4 metallocene based single site catalysts are generally known for polymerization reactions. See, generally, “Chemistry of Cationic Dicyclopentadienyl Group 4 Metal-Alkyl Complexes", Jordan, Adv. Organometallic Chem. 1991, 32,325-153, and the references therein, all of which is incorporated herein by reference.
  • metallocene catalysts One application for metallocene catalysts is producing isotactic polypropylene.
  • An extensive body of scientific literature examines catalyst structures, mechanism and polymers prepared by metallocene catalysts. See, e.g., Resconi et al., "Selectivity in Propene Polymerization with Metallocene Catalysts," Chem. Rev. 2000, 100, 1253-1345 and G.W. Coates, "Precise Control of Polyolefin Stereochemistry Using Single-Site Metal Catalysts," Chem. Rev. 2000, 100, 1223-1252 and the references cited in these review articles.
  • Isotactic polypropylene has historically been produced with heterogeneous catalysts that may be described as a catalyst on a solid support (e.g., titanium tetrachloride and aluminum alkyls and additional modifiers or "donors" on magnesium dichloride).
  • This process typically uses hydrogen to control the molecular weight and electron-donor compounds to control the isotacticity. See also EP 0 622 380, EP 0 292 134 and U.S. Patents 4,971,936, 5,093,415, 4,297,465, 5,385,993 and 6,239,236.
  • the invention features ligands, compositions and metal complexes that are useful in catalysts for olefin polymerization and other transformations, as well as methods for preparing the ligands and for using the compositions or complexes in catalytic transformations such as olefin polymerization,
  • the ligands have a phenol- heterocyclic structure, as will be discussed in more detail below.
  • Catalysts according to the invention can be provided by compositions including a ligand, a metal precursor, and optionally an activator, combination of activators, or an activator technique.
  • catalysts can be provided by metal-ligand complexes and optionally may additionally include an activator, combination of activators or activator technique.
  • the invention provides compositions of matter, including ligands, compositions and metal-ligand complexes, that include a compound characterized by the formula (I):
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are the same or different and are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heteroalkyl, substituted heteroalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkoxy, aryloxy, halo, silyl, boryl, phosphino, amino, thioalkyl, tliioaryl, nitro, and combinations thereof, with the exception that R 1 may not be hydrogen, optionally two or more of R 1 , R 2 , R 3 and R 4 may be joined to form a fused ring system having up to 50 atoms, not counting hydrogen atoms, and optionally two or more of R 5 , R 6 and R 7 may be joined to form a fused ring
  • X 1 is N or C
  • X 2 is O
  • X 3 is O
  • X 4 is O
  • each n ⁇ n", and n'" are each independently 0 or 1, provided that the heteroatom containing ring system is heteroaromatic, provided combinations of X 1 , X 2 ; X 1 , X 3 ; and X 1 , X 4 are not both N and X 1 , X 2 and X 3 are not all N.
  • Additional compounds that are not included are those where X 1 , X 3 , X 4 are each N, X 2 is C, R 5 is H and R 1 is selected from the group consisting of t- butyl, -CMe 2 Et, -C(Et) 3 , -CMe 2 Ph, -C(Ph) 3 , -Si(Et) 3 , and -Si(Ph) 3 , and when R 1 is F, R 3 is F, X 1 , X 2 , X 3 are all C, X 4 is N, R 5 , R 6 are each H and R 7 is t-butyl.
  • R 1 is selected from the group consisting of alkyl, substituted alkyl, naphthyl, substituted naphthyl, carbazolyl, substituted carbazolyl, phenyl, substituted phenyl, indolyl, substituted indolyl, adamantyl, substituted adamantyl, thiophenyl, substituted thiophenyl, benzofuranyl, substituted benzofuranyl, benzothiophenyl and substituted benzothiophenyl.
  • R 7 is selected from the group consisting of alkyl, substituted alkyl, naphthyl, substituted naphthyl, carbazolyl, substituted carbazolyl, phenyl, substituted phenyl, indolyl, substituted indolyl, adamantyl, substituted adamantyl, thiophenyl, substituted thiophenyl, benzofuranyl, substituted benzofuranyl, benzothiophenyl and substituted benzothiophenyl and in particular, R 1 is selected from the group consisting of t-butyl, naphthyl, substituted naphthyl, carbazolyl, substituted carbazolyl, phenyl and substituted phenyl and R 7 is selected from the group consisting of substituted phenyl and anthracenyl.
  • X 1 is C
  • X 2 is O
  • X 3 is N
  • X 4 is CR 7 and are referred to as formulae (Ia).
  • R 1 is an alkyl, substituted alkyl, aryl or a substituted aryl.
  • R 3 is an alkyl or a substituted alkyl.
  • R 7 is an aryl or a substituted aryl.
  • X 1 is C
  • X 2 is N
  • X 3 is O
  • X 4 is CR 7 and are referred to as formulae (Ib).
  • R 1 is an alkyl or a substituted alkyl.
  • R 3 is an alkyl or a substituted alkyl.
  • R 7 is an aryl or a substituted aryl.
  • X 1 is C
  • X 2 is NR 5
  • X 3 is CR 6
  • X 4 is CR 7 and are referred to as formulae (Ic).
  • R 1 is an alkyl, substituted alkyl, aryl, or a substituted aryl.
  • R 3 is an alkyl or a substituted alkyl.
  • R 5 is an alkyl or a substituted alkyl.
  • R 6 is an aryl or a substituted aryl.
  • R 7 is an aryl or a substituted aryl.
  • X 1 is C
  • X 2 is S
  • X 3 is CR 6
  • X 4 is CR 7 and are referred to as formulae (Id)
  • R 1 is an aryl, substituted aryl, alkyl or a substituted alkyl.
  • R 3 is an alkyl or a substituted alkyl.
  • R 6 is a hydrogen
  • R 7 is bromide, phenyl, substituted phenyl, naplithyl, substituted naphthyl, anthracenyl, substituted anthracenyl, or a hydrogen.
  • X4s C, X 2 is CR 5 , X 3 is S and X 4 is CR 7 and are referred to as formulae (Ie).
  • R 1 is an aryl or a substituted aryl.
  • R 3 is a hydrogen, an alkyl or .a substituted alkyl.
  • R 5 is a hydrogen
  • R 7 is an aryl or a substituted aryl.
  • X 1 is N
  • X 2 is CR 5
  • X 3 is CR 6
  • X 4 is CR 7 and are referred to as formulae (If).
  • R 1 is an aryl or substituted aryl.
  • R 3 is an alkyl or substituted alkyl.
  • R 5 is a hydrogen
  • R 6 is a hydrogen
  • R 7 is an alkyl or phenyl.
  • X 1 is C
  • X 2 is CR 5
  • X 3 is CR 6
  • X 4 is NR 7 and are referred to as formulae (Ig).
  • R 1 is a halogen.
  • R 2 is a hydrogen or methyl.
  • R 3 is a halogen.
  • R 5 is a hydrogen.
  • R 6 is a hydrogen.
  • R 7 is a hydrogen, an alkyl or a substituted alkyl.
  • R 1 and R 3 are not both F and R 7 is not t- butyl.
  • X 1 is C, X 2 is CR 5 , X 3 is NR 6 and X 4 is CR 7 and are referred to as formulae (Di).
  • X 1 is C, X 2 is O, X 3 is CR 6 and X 4 is CR 7 and are referred to as formulae (Ii).
  • X 1 Is C, X 2 is CR 5 , X 3 is O and X 4 is CR 7 and are referred to as formulae (Ij).
  • Preferred R groups for these additional embodiments are cliosed from those disclosed for formula (I) through (Ig).
  • compositions of matter including ligands, compositions and metal-ligand complexes, that include a compound characterized by the formula (II):
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 are the same or different and are each independent of one another and are as described above.
  • X 1 is N or C
  • X 2 is N or CR 5
  • X 3 is N or CR 6
  • X 4 is N or CR 7
  • the heteroatom containing ring system is heteroaromatic
  • R 5 , R 6 and R 7 are each H and R 1 is selected from the group consisting of t-butyl, -CMe 2 Et, -C(Et) 3 , -CMe 2 Ph, - C(Ph) 3 , -Si(Et) 3 , and -Si(Ph) 3 , are not included.
  • R 1 is selected from the group consisting of alkyl, substituted alkyl, naphthyl, substituted naphthyl, carbazolyl, substituted carbazolyl, phenyl, substituted phenyl, indolyl, substituted indolyl, adamantyl, substituted adamantyl, tliioplienyl, substituted thiophenyl, benzofuranyl, substituted benzofuranyl, benzothiophenyl and substituted benzothioplienyl.
  • R 7 is selected from the group consisting of alkyl, substituted alkyl, naphthyl, substituted naphthyl, carbazolyl, substituted carbazolyl, phenyl, substituted phenyl, indolyl, substituted indolyl, adamantyl, substituted adamantyl, thiophenyl, substituted thiophenyl, benzofuranyl, substituted benzofuranyl, benzothioplienyl and substituted benzothiophenyl
  • R 1 is selected from the group consisting of t-butyl, naphthyl, substituted naphthyl, carbazolyl, substituted carbazolyl, phenyl and substituted phenyl and R 7 is selected from the group consisting of substituted phenyl and anthracenyl.
  • CR 6 and X 4 is CR 7 and are referred to as formulae (Ha).
  • formulae (Ha) In one aspect of formula (Ha),
  • R 1 is an alkyl, substituted alkyl, aryl, or a substituted aryl. In another aspect of formula
  • R 3 is a hydrogen, an alkyl or a substituted alkyl.
  • R 6 is an aryl or a substituted aryl.
  • R 7 is an aryl or a substituted aryl.
  • R 7 is a disubstituted phenyl group, and in particular, a 2,6 disubstituted phenyl group.
  • compositions of matter including ligands, compositions and metal-ligand complexes, that include a compound characterized by the formula (III):
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , and R 11 are the same or different and are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heteroalkyl, substituted heteroalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkoxy, aryloxy, halo, silyl, boryl, phosphino, amino, thioalkyl, thioaryl, nitro, and combinations thereof, with the exception that R 1 may not be hydrogen, optionally two or more of R 1 , R 2 , R 3 and R 4 may be joined to form a fused ring system having up to 50 atoms, not counting hydrogen atoms, and optionally two or more of R 8 , R 9 , R 10 and R 11
  • X 1 is N or C
  • X 2 is O, S, N(R 5 ) n > or CR 5 , wherein n' is 0 or 1, provided that the heteroatom containing ring system is heteroaromatic, provided X 1 and X 2 are not both N.
  • R 1 is selected from the group consisting of t-butyl, naphthyl, substituted naphthyl, carbazolyl, ⁇ substituted carbazolyl, phenyl and substituted phenyl.
  • X 1 is C
  • X 2 is NR 5 and are referred to as formulae (Ilia).
  • R 1 is an alkyl, substituted alkyl, aryl or a substituted aryl.
  • R 3 is a hydrogen, alkyl or substituted alkyl.
  • R 5 is an alkyl or substituted alkyl.
  • X 1 is C and X 2 is S and are referred to as formulae (HIb).
  • R 1 is an alkyl or a substituted alkyl.
  • R 3 is a hydrogen, an alkyl or a substituted alkyl.
  • R 1 is an alkyl or substituted alkyl.
  • R 3 is an alkyl or substituted alkyl.
  • compositions of matter including ligands, compositions and metal-ligand complexes, that include a compound characterized by the formula (FV):
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , and R 11 are the same or different and are each independent of each other and are as described above.
  • X 1 is C
  • X 2 is N or CR 5 , provided that the heteroatom containing ring system is heteroaromatic.
  • R 1 is selected from the group consisting of t-butyl, naphthyl, substituted naphthyl, carbazolyl, substituted carbazolyl, phenyl and substituted phenyl.
  • X 1 is C and X 2 is N and are referred to as formulae (IVa).
  • R 1 is an alkyl, substituted alkyl, aryl or substituted aryl.
  • R 3 is a hydrogen, an alkyl or a substituted alkyl.
  • R 9 is a hydrogen, halogen, alkyl, substituted alkyl, or an alkoxy.
  • R 10 is a hydrogen, halogen, alkyl, or a substituted alkyl.
  • the invention provides compositions of matter, including ligands, compositions and metal-ligand complexes, that include a compound characterized by the formula (V):
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , and R 11 are the same or different and are each, independent of each other and are as described above.
  • X 1 is N or C
  • X 2 is O, S, N(R 5 ) n . or CR 5 , wherein n' is 0 or 1, provided that the heteroatom containing ring system is heteroaromatic, provided when X 1 and X 2 are both N, then:
  • R 1 is t-butyl
  • R 2 is H
  • R 3 is Me
  • R 4 is H
  • R 8 , R 9 , R 11 are each H and R 10 is Cl;
  • R 1 is /-propyl
  • R 2 is H
  • R 3 is t-butyl
  • R 4 , R 8 , R 9 , R 10 and R 11 are each H;
  • R 1 is t-butyl
  • R 2 is H
  • R 3 is t-butyl
  • R 4 is H
  • R 8 , R 9 , R 11 are each H and R 10 is Cl;
  • R 1 is 1,1-dimethylpropyl
  • R 2 is H
  • R 3 is 1,1-dimethylpropyl
  • R 11 are each H
  • R 1 is isopropylbenzyl
  • R 2 is H
  • R 3 is isopropylbenzyl
  • R 4 is H
  • R 8 , R 9 , R 11 are each H and R 10 is Cl;
  • R 1 is t-butyl
  • R 2 is H
  • R 3 is t-butyl
  • R 4 is H
  • R 8 , R 9 , R 11 are each H and R 10 is F;
  • R 1 is t-butyl
  • R 2 is H
  • R 3 is t-butyl
  • R 4 is H
  • R 8 , R 11 are each H
  • R 9 and R 10 are each F;
  • R 1 is t-butyl
  • R 2 is H
  • R 3 is t-butyl
  • R 4 is H
  • R 8 , R 11 are each H
  • R 9 and R 10 are each Cl
  • R 1 is t-butyl
  • R 2 is H
  • R 3 is t-butyl
  • R 4 is H
  • R 8 , R 9 , R 11 are each H and R 10 is -
  • R 1 is t-butyl
  • R 2 is H
  • R 3 is t-butyl
  • R 4 is H
  • R 8 , R 9 , R 11 are each H and R 10 is -
  • R 1 is t-butyl
  • R 2 is H
  • R 3 is t-butyl
  • R 4 is H
  • R 8 , R 11 are each H
  • R 9 and R 10 is are each Me
  • R 1 is t-butyl
  • R 2 is H
  • R 3 is -OMe
  • R 4 is H
  • R 8 , R 9 , R 11 are each H and R 10 is Cl;
  • R 1 is phenyl
  • R 2 is H
  • R 3 is t-butyl
  • R 4 is H
  • R 8 , R 9 , R 11 are each H and R 10 is Cl;
  • R 1 is t-butyl
  • R 2 is H
  • R 3 is -Me
  • R 4 is H
  • R 8 , R 9 , R 11 are each H and R 10 is Cl;
  • R 1 is 2,4,6-trimethyl ⁇ henyl
  • R 2 is H
  • R 3 is -Me
  • R 4 is H
  • R 8 , R 9 , R 11 are each H and R 10 is Cl;
  • R 1 is 1-naphthyl
  • R 2 is H
  • R 3 is -Me
  • R 4 is H
  • R 8 , R 9 , R 11 are each H and R 10 is Cl;
  • R 1 is 9-anthracenyl
  • R 2 is H
  • R 3 is -Me
  • R 4 is H
  • R 8 , R 9 , R 11 are each H
  • R 10 is
  • R 1 is 3,5-difluorophenyl
  • R 2 is H
  • R 3 is -Me
  • R 4 is H
  • R 8 , R 9 , R 11 are each H and
  • R 10 is Cl
  • R 1 is an alkyldiarylsilyl or dialkylarylsilyl
  • R 2 is H
  • R 3 is -Me
  • R 4 is H
  • R 8 , R 9 , R 11 are each H and R 10 is Cl; not included.
  • R 1 is selected from the group consisting of t-butyl, naphthyl, substituted naphthyl, carbazolyl, substituted carbazolyl, phenyl and substituted phenyl.
  • compositions according to the invention can include a metal precursor or activated metal precursor including a metal selected from groups 3-6 and the lanthanide series of the periodic table of elements, and one or more optional activators.
  • the metal precursor can be a compound characterized by the general formula M(L) m , where M is a metal selected from the group consisting of groups 3-6 and lanthanides of the periodic table of elements, and each L is a ligand independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, heteroalkyl, allyl, diene, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, aryl, heteroaryl, alkoxy, aryloxy, boryl, silyl, amino, phosphino, ether, thioether, phosphine, amine, carboxylate, alkylthio, arylthio, 1,3-dionate,
  • two or more L groups can be joined into a ring structure,
  • one or more of the ligands L can be ionically bonded to the metal M.
  • m is 1, 2, 3, 4, 5, or 6.
  • M can be Ti, Zr, and Hf.
  • the invention features metal-ligand complexes characterized by the formula (VI): where M, L and X 1 are as described above with the broken bonds representing the compounds having formulae (I) through (Ig), (III) through (HId) and (V) as described above, x is 1, 2, 3, or 4 and m" is 0, 1, 2, 3 or 4.
  • formulae (VI) includes those compounds having formulae (II), (Ha) and (IV) as described above, the nitrogen includes a hydrogen, and m' and x are as described above.
  • the dashed bond shown between the nitrogen atom with M depicted in formula (VI) can be dative, nonexistent, or covalent.
  • the phrase the bond between the heteroaromatic nitrogen (N) and the metal (M) is dative or absent is used to indicate additionally that the bond may attach or detach such that the bond fluxuates between dative and absent.
  • the complex may include more than one metal (M) and one or more ligands, each independent of one another, and the ligand to metal ratio may be fractional.
  • Particular embodiments can include one or more of the following features.
  • the complex can be characterized by the formula (VII):
  • the invention features metal-ligand complexes characterized by the formula (VIII):
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X 1 , X 2 , X 3 and X 4 are as described above for compounds of formulae (II) and (Ha), M and L are as described above, x is 1 or 2 and m" is ⁇ , 1, 2, 3, or 4.
  • R 7 is a disubstituted phenyl group, and in particular, a 2,6 disubstituted phenyl group.
  • the invention features metal-ligand complexes characterized by the formula (IX):
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , X 1 and X 2 are as described above for compounds of formulae (III) through formulae (HId), M and L are as described above, x is 1, 2, 3,, or 4 and m" is 0, 1, 2, 3, or 4 and the bond between the heteroaromatic nitrogen (N) and the metal (M) is dative or absent.
  • the invention features metal-ligand complexes characterized by the formula (X): where R 1 , R z , R ⁇ , R ⁇ R ⁇ R 6 , R y , R i ⁇ , R 11 , X 1 and X z are as described above for compounds of formulae (IV) and (IVa), M and L are as described above, x is 1 or 2 and m" is 0, 1, 2, 3, or 4.
  • the invention features metal-ligand complexes characterized by the formula (XI):
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , X 1 and X 2 are as described above for compounds of formulae (V), M and L are as described above, x is 1, 2, 3, or 4 and m" is
  • R 1 and R 7 can be thiophenyl, substituted thiophenyl, carbazole, substituted carbazoles, indoles and substituted indoles.
  • the invention provides bis-ligand complexes, as well as compositions where the ratio of metal to ligand is about one to two.
  • these bis-ligand systems are those where x is 2 in any of the above metal complex formulae, and in other embodiments, the bis-ligand systems have one ancillary ligand as described in the above formulae and a second ancillary ligand that can generally be within the definition of L.
  • a bis-ligand complex can be
  • each R , R , R , R , R , R , R are the same or different and are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heteroalkyl, substituted heteroalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkoxy, aryloxy, halo, silyl, boryl, phosphino, amino, thioalkyl, thioaryl, nitro, and combinations thereof, with the exception that R may not be hydrogen, optionally two or more of R 1 , R 2 , R 3 and R 4 on the same ring in the formula may be joined to form a fused ring system having up to 50 atoms, not counting hydrogen atoms, and optionally two or more of R 5 , R 6 and R 7 on the same ring In the exception that R may not be hydrogen,
  • X 7 is O, S, N(R 6 ) n - or CR 6
  • X 8 is O, S, N(R 7 ) n - or CR 7 , wherein each n', n", and n'" are each independently 0 or 1, provided that the heteroatom containing ring system is heteroaromatic; and further provided that in the selection of the C, N, O or S atom, at least, either X 1 and X 5 are different or X 2 and X 6 are different or X 3 and X 7 are different or X 4 and X 8 are different; wherein M is a metal selected from the group consisting of groups 3 through 6 of the periodic table elements and lanthanides; wherein each L is independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, heteroalkyl, allyl, diene, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, aryl, heteroaryl
  • the invention provides arrays of materials.
  • the arrays include a substrate having at least 8 members associated with regions of the substrate. Each array member is different from the other members of the array. Each array member includes a compound, composition or complex according to one of the aspects described above.
  • the invention provides catalytic methods.
  • one or more reagents is reacted in the presence of a catalyst comprising a composition or complex as described above, and optionally one or more activators, under conditions sufficient to yield one or more reaction products.
  • the invention provides polymerization processes that employ the composition or complexes of the invention, optionally in the presence of at least one activator.
  • the activator can include an ion forming activator and, optionally, a group 13 reagent.
  • the activator can include an alumoxane.
  • the invention provides a process for the polymerization of an alpha-olefin.
  • at least one alpha-olefin is polymerized in the presence of a catalyst formed from a composition or complex of the invention, optionally in the presence of one or more activators, under polymerization conditions sufficient to form a substantially stereoregular polymer.
  • the invention provides a process for polymerizing ethylene and at least one alpha-olefin.
  • ethylene is polymerized in the presence of at least one alpha-olefin in the presence of a catalyst formed from a composition or complex of the invention, optionally in the presence of one or more activators.
  • the at least one alpha-olefin can include propylene, 1-butene, 1-hexene, 1-octene, 1-decene, styrene or substituted styrene.
  • the process can be a solution process, and can be operated under polymerization conditions that include a temperature of at least 100°C, or at least 125°C.
  • the invention provides a process for polymerizing at least one monomer.
  • the process includes providing a reactor with reactor contents including at least one polymerizable monomer and a composition or complex of the invention, and subjecting the reactor contents to polymerization conditions.
  • the at least one polymerizable monomer can include ethylene and propylene, ethylene and 1-hexene, ethylene and 1-butene, 1-octene, 1-decene, ethylene and styrene, ethylene and a cyclic alkene, ethylene and a diene, or ethylene, propylene, and a diene selected from the group consisting of ethylidenenorbornene, dicyclopentadiene, and 1,4-hexadiene.
  • the invention provides a process for the polymerization of a polymerizable monomer.
  • a composition or complex of the invention is provided, the composition or complex is optionally activated, and at least one polymerizable monomer is polymerized in the presence of the activated composition or complex to produce a distribution of product polymers that is at least bimodal by one or more of molecular weight or composition.
  • the invention can be implemented to provide one or more of the following advantages.
  • the ligands, compositions, complexes and polymerization methods of the invention can be used to provide catalysts exhibiting enhanced activity.
  • Catalysts incorporating the ligands, compositions and/or complexes can be used to catalyze a variety of transformations, such as olefin oligomerization (specifically dimerization, trimerization and tetramerization) or polymerization.
  • olefin oligomerization specifically dimerization, trimerization and tetramerization
  • polymerization By selecting an appropriate ligand and metal, compositions and/or complexes can be obtained to provide for desired properties in the resulting product.
  • polymers produced using the ligands, compositions, complexes, and methods of the invention can exhibit higher (or lower) melting points, higher (or lower) molecular weights, and/or higher (or lower) polydispersities, than polymers produced using prior known catalysts.
  • polymer products having bi- or multi-modal distributions of product composition and/or molecular weight can be obtained by selecting a single catalyst precursor and activating it under certain conditions.
  • Catalysts incorporating the ligands, compositions and/or complexes can be used according to the polymerization methods of the invention to produce polymers under commercially desirable polymerization conditions.
  • Catalysts incorporating the ligands, compositions and complexes of the invention can exhibit catalytic activity at higher temperatures than prior known catalysts.
  • compositions and complexes of the invention can exhibit higher (or lower) comonomer incorporation than processes involving prior known catalysts.
  • Chiral compositions and/or complexes according to the invention can be used to catalyze stereoselective, enantioselective or diastereoselective transformations.
  • Figure 1 is an X-ray structure determination of complex M1 of the invention.
  • Figure 2 is a list of certain ligands that comprise Tables 1-7, in accord with the invention herein.
  • Figure 3 is a list of certain metal-ligand complexes in accord with the inventions herein.
  • the invention provides ligands, compositions and complexes that are useful as catalysts for a variety of transformations, including olefin polymerization reactions.
  • the phrase "characterized by the formula” is not intended to be limiting and is used in the same way that "comprising” is commonly used.
  • the term “independently selected” is used herein to indicate that the groups in question ⁇ e.g., R 1 , R 2 , R 3 , R 4 , R 5 , etc. - can be identical or different (e.g., R 1 , R 2 , R 3 , R 4 , R 5 , etc.
  • R 1 and R 2 may be a substituted alkyl and R 3 may be an aryl, etc.).
  • R 1 and R 2 may be a substituted alkyl and R 3 may be an aryl, etc.
  • R 1 and R 2 may be a substituted alkyl and R 3 may be an aryl, etc.
  • R 3 may be an aryl, etc.
  • R 1 and R 2 may be a substituted alkyl and R 3 may be an aryl, etc.
  • R 3 may be an aryl, etc.
  • substituted as in “substituted hydrocarbyl,” “substituted aryl,” “substituted alkyl,” and the like, means that in the group in question ⁇ i.e., the hydrocarbyl, alkyl, aryl or other moiety that follows the term), at least one hydrogen atom bound to a carbon atom is replaced with one or more substituent groups such as hydroxy, alkoxy, alkylthio, phosphino, amino, halo, silyl, and the like.
  • substituent groups such as hydroxy, alkoxy, alkylthio, phosphino, amino, halo, silyl, and the like.
  • substituted alkyl, alkenyl and alkynyl is to be interpreted as “substituted alkyl, substituted alkenyl and substituted alkynyl.”
  • optionally substituted alkyl, alkenyl and alkynyl is to be interpreted as “optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl.”
  • saturated refers to the lack of double and triple bonds between atoms of a radical group such as ethyl, cyclohexyl, pyrrolidinyl, and the like.
  • unsaturated refers to the presence of one or more double and triple bonds between atoms of a radical group such as vinyl, allyl, acetylide, oxazolinyl, cyclohexenyl, acetyl and the like, and specifically includes alkenyl and alkynyl groups, as well as groups in which double bonds are delocalized, as in aryl and heteroaryl groups as defined below.
  • cyclo and cyclic are used herein to refer to saturated or unsaturated radicals containing a single ring or multiple condensed rings.
  • Suitable cyclic moieties include, for example, cyclopentyl, cyclohexyl, cyclooctenyl, bicyclooctyl, phenyl, napthyl, pyrrolylj furyl, thiophenyl, imidazolyl, and the like,
  • cyclic moieties include between 3 and 200 atoms other than hydrogen, between 3 and 50 atoms other than hydrogen or between 3 and 20 atoms other than hydrogen.
  • hydrocarbyl refers to hydrocarbyl radicals containing 1 to about 50 carbon atoms, specifically 1 to about 24 carbon atoms, most specifically 1 to about 16 carbon atoms, including branched or unbranched, cyclic or acyclic, saturated or unsaturated species, such as alkyl groups, alkenyl groups, aryl groups, and the like.
  • alkyl refers to a branched or unbranched saturated hydrocarbon group typically although not necessarily containing 1 to about 50 carbon atoms, such as methyl, ethyl, ⁇ -propyl, isopropyl, «-butyl, isobutyl, sec-butyl, t-butyl, octyl, decyl, and the like, as well as cycloalkyl groups such as cyclopentyl, cyclohexyl and the like. Generally, although again not necessarily, alkyl groups herein may contain 1 to about 20 carbon atoms.
  • alkenyl refers to a branched or unbranched, cyclic or acyclic hydrocarbon group typically although not necessarily containing 2 to about 50 carbon atoms and at least one double bond, such as ethenyl, r ⁇ -propenyl, isopropenyl, n- butenyl, isobutenyl, octenyl, decenyl, and the like. Generally, although again not necessarily, alkenyl groups herein contain 2 to about 20 carbon atoms.
  • alkynyl refers to a branched or unbranched, cyclic or acyclic hydrocarbon group typically although not necessarily containing 2 to about 50 carbon atoms and at least one triple bond, such as ethynyl, n-propynyl, isopropynyl, n- butynyl, isobutynyl, octynyl, decynyl, and the like. Generally, although again not necessarily, alkynyl groups herein may have 2 to about 20 carbon atoms.
  • aromatic is used in its usual sense, including unsaturation that is essentially delocalized across several bonds around a ring.
  • aryl refers to a group containing an aromatic ring.
  • Aryl groups herein include groups containing a single aromatic ring or multiple aromatic rings that are fused together, linked covalently, or linked to a common group such as a methylene or ethylene moiety. More specific aryl groups contain one aromatic ring or two or three fused or linked aromatic rings, e.g., phenyl, naphthyl, biphenyl, anthracenyl, or phenanthrenyl.
  • aryl substituents include 1 to about 200 atoms other than hydrogen, typically 1 to about 50 atoms other than hydrogen, and specifically 1 to about 20 atoms other than hydrogen,
  • multi-ring moieties are substituents and in such embodiments the multi-ring moiety can be attached at an appropriate atom.
  • naphthyl can be 1 -naphthyl or 2-naphthyl
  • anthracenyl can be 1 -anthracenyl, 2-anthracenyl or 9-anthracenyl
  • phenanthrenyl can be 1 -phenanthrenyl, 2-phenanthrenyl, 3 -phenanthrenyl, 4-phenanthrenyl or 9- phenanthrenyl.
  • alkoxy as used herein intends an alkyl group bound through a single, terminal ether linkage; that is, an "alkoxy" group may be represented as -O-alkyl where alkyl is as defined above.
  • aryloxy is used in a similar fashion, and may be represented as -O-aryl, with aryl as defined below.
  • hydroxy refers to -OH.
  • alkylthio intends an alkyl group bound through a single, terminal thioether linkage; that is, an "alkylthio” group may be represented as -S-alkyl where alkyl is as defined above.
  • arylthio is used similarly, and may be represented as -S-aryl, with aryl as defined below.
  • mercapto refers to -SH.
  • halo and halogen are used in the conventional sense to refer to a chloro, bromo, fluoro or iodo radical.
  • heterocycle and “heterocyclic” refer to a cyclic radical, including ring-fused systems, including heteroaryl groups as defined below, in which one or more carbon atoms in a ring is replaced with a heteroatom - that is, an atom other than carbon, such as nitrogen, oxygen, sulfur, phosphorus, boron or silicon.
  • Heterocycles and heterocyclic groups include saturated and unsaturated moieties, including heteroaryl groups as defined below.
  • heterocycles include pyrrolidine, pyrroline, furan, tetrahydrofuran, thiophene, imidazole, oxazole, thiazole, indole, and the like, including any isomers of these. Additional heterocycles are described, for example, in Alan R. Katritzky, Handbook of Heterocyclic Chemisti ⁇ , Pergammon Press, 1985, and in Comprehensive Heterocyclic Chemistry, A.R. Katritzky et ah, eds, Elsevier, 2d. ed., 1996.
  • the term "metallocycle” refers to a heterocycle in which one or more of the heteroatoms in the ring or rings is a metal.
  • heteroaryl refers to an aryl radical that includes one or more heteroatoms in the aromatic ring.
  • Specific heteroaryl groups include groups containing heteroaromatic rings such as thiophene, pyridine, pyrazine, isoxazole, pyrazole, pyrrole, furan, thiazole, oxazole, imidazole, isothiazole, oxadiazole, triazole, and benzo-fused analogues of these rings, such as indole, carbazole, benzofuran, benzothiophene, benzimidiazole, benzthiazole, benzoxazoles, indazole and the like and isomers thereof, e.g., reverse isomers.
  • heteroalkyl refers to a molecule or molecular fragment in which one or more carbon atoms is replaced with a heteroatom.
  • heteroalkyl refers to an alkyl substituent that is heteroatom-containing.
  • heteroatom-containing alkyl, alkenyl and alkynyl is to be interpreted as “heteroatom-containing alkyl, heteroatom-contaming alkenyl and heteroatom-containing alkynyl.”
  • divalent as in “divalent hydrocarbyl”, “divalent alkyl”, “divalent aryl” and the like, is meant that the hydrocarbyl, alkyl, aryl or other moiety is bonded at two points to atoms, molecules or moieties with the two bonding points being covalent bonds.
  • silyl refers to the -SiZ 1 Z 2 Z 3 radical, where each of Z 1 , Z 2 , and Z 3 is independently selected from the group consisting of hydrogen and optionally substituted alkyl, alkenyl, alkynyl, heteroatom-containing alkyl, heteroatom- containing alkenyl, heteroatom-containing alkynyl, aryl, heteroaryl, alkoxy, aryloxy, amino, silyl and combinations thereof.
  • boryl refers to the -BZ 1 Z 2 group, where each of
  • Z 1 and Z 2 is as defined above.
  • phosphino refers to the group -PZ Z , where each of Z and Z is as defined above.
  • phosphine refers to the group :PZ 1 Z 2 Z 3 , where each of Z 1 , Z 3 and Z 2 is as defined above.
  • amino is used herein to refer to the group -NZ 1 Z 2 , where each of Z 1 and Z 2 is as defined above.
  • amine is used herein to refer to the group INZ 1 Z 2 Z 3 , where each of Z 1 , Z 2 and Z 3 is as defined above.
  • ligand binding is sometimes referred to as (2,1) complexation or (2,2) complexation, with the first number representing the number of coordinating atoms and second number representing the number of anionic sites on the phenol-heterocycle ligand, when the metal-ligand bonding is considered from an ionic bonding model perspective, with the metal considered to be cationic and the ligand considered to be anionic.
  • a (2,1) complex may be considered to be a complex in which the phenol-heterocycle ligand is bound to the metal center via one covalent bond and one dative bond
  • a (2,2) complex may be considered to be a complex in which the phenol-heterocycle ligand is bound to the metal' center via two covalent bonds.
  • Examples of (2,1) complexation include the complex examples labeled M1 through M30 as listed below.
  • a covalent bond or dative bond may be formed from R 1 , R 7 or R 11 to the metal, to form a (3,2) complex, or (3,1) complex respectively.
  • R 1 , R 7 or R 11 is an aryl or heteroaryl
  • C-H activation may occur to form a (3,2) complex
  • R 1 , R 7 or R 11 is a heteroatom-containing group
  • a dative bond may be found from heteroatom to metal to give a (3,1) complex.
  • the complexes can include "mono" ligand and
  • the ligands according to the invention can be characterized broadly as monoanionic ligands having a phenol and a heterocyclic or substituted heterocyclic group. Preferred ligand substituents for some particular monomers are described in more detail below.
  • the ligands of the invention can be characterized by the following (I):
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heteroalkyl, substituted heteroalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkoxy, aryloxy, halo, silyl, boryl, phosphino, amino, thioalkyl, thioaryl, nitro, and combinations thereof, with the exception that R 1 may not be hydrogen, optionally two or more of R 1 , R 2 , R 3 and R 4 may be joined to form a fused ring system having up to 50 atoms, not counting hydrogen atoms, and optionally two or more of R 5 , R 6 and R 7 may be joined to form a fused ring system having up to 50 atoms
  • X 1 is N or C
  • X 2 is O, S, N(R 5 V or CR 5 ,
  • X 3 is O, S, N(R 6 V or CR 6
  • X 4 is O, S, N(R 7 V- or CR 7 , wherein each n ⁇ n", and n'" are each independently 0 or 1, provided that the heteroatom containing ring system is heteroaromatic, provided combinations of X 1 , X 2 ; X 1 , X 3 ; and X 1 , X 4 are not both N and X 1 , X 2 and X 3 are not all N.
  • Additional compounds that are not included are those where X 1 , X 3 , X 4 are each N, X 2 is C, R 5 is H and R 1 is selected from the group consisting of t- butyl, -CMe 2 Et, -C(Et) 3 , -CMe 2 Ph, -C(Ph) 3 , -Si(Et) 3 , and -Si(Ph) 3 , and when R 1 is F, R 3 is F, X 1 , X 2 , X 3 are all C, X 4 is N, R 5 , R 6 are each H and R 7 is t-butyl. [00114] Additionally, the compounds and complexes disclosed in US Patent No.
  • R 1 is selected from the group consisting of alkyl, substituted alkyl, naphthyl, substituted naphthyl, carbazolyl, substituted carbazolyl, phenyl, substituted phenyl, indolyl, substituted indolyl, adamantyl, substituted adamantyl, thiophenyl, substituted thiophenyl, benzofuranyl, substituted benzofuranyl, benzothiophenyl and substituted benzothiophenyl.
  • R 7 is selected from the group consisting of alkyl, substituted alkyl, naphthyl, substituted naphthyl, carbazolyl, substituted carbazolyl, phenyl, substituted phenyl, indolyl, substituted indolyl, adamantyl, substituted adamantyl, thiophenyl, substituted thiophenyl, benzofuranyl, substituted benzofuranyl, benzothiophenyl and substituted benzothiophenyl and in particular, R 1 is selected from the group consisting of t-butyl, naphthyl, substituted naphthyl, carbazolyl, substituted carbazolyl, phenyl and substituted phenyl and R 7 is selected from the group consisting of substituted phenyl and anthracenyl.
  • X 1 is C,
  • X 3 is N and X 4 is CR 7 and are referred to as formulae (Ia):
  • R 1 is an alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl.
  • R 3 is an alkyl or a substituted alkyl.
  • R 7 is an aryl or a substituted aryl.
  • Specific examples of ligands within the scope of formula (Ia) include those set out in Figure 2 as "A" ligands.
  • R 1 is an alkyl or a substituted alkyl.
  • R 3 is an alkyl or a substituted alkyl.
  • R 7 is an aryl or a substituted aryl.
  • Specific examples of ligands within the scope of formula (Ib) includes those set out in Figure 2 as "B" ligands.
  • X 1 is C
  • X 2 is NR 5
  • X 3 is CR 6
  • X 4 is CR 7 and are referred to as formulae (Ic):
  • R 1 is an alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl or a substituted heteroaryl.
  • R 3 is an alkyl or a substituted alkyl.
  • R 5 is an alkyl or a substituted alkyl.
  • R 6 is an aryl or a substituted aryl.
  • R 7 is an aryl or a substituted aryl. Suitable examples of ligands within the scope of formula (Ic) include those set out in Figure 2 as "F" ligands.
  • R 1 is an aryl, substituted aryl; alkyl, substituted alkyl, heteroaryl or a substituted heteroaryl.
  • R 3 is an alkyl or a substituted alkyl.
  • R 6 is a hydrogen.
  • R 7 is a halide, phenyl, substituted phenyl, naphthyl, substituted naphthyl, anthracenyl, substituted anthracenyl, or a hydrogen.
  • Specific examples of ligands within the scope of formula (Id) include those set out in Figure 5 as "C" ligands.
  • R 1 is an aryl, substituted aryl, hetroaryl or substituted heteroaryl.
  • R 3 is an alkyl or a substituted alkyl.
  • R 5 is a hydrogen.
  • R 7 is an aryl or a substituted aryl.
  • R 1 is an aryl or substituted aryl.
  • R 3 is an alkyl or substituted alkyl.
  • R 5 is a hydrogen.
  • R 6 is a hydrogen.
  • R 7 is an alkyl, substituted alkyl, phenyl or substituted phenyl. Suitable examples of ligands within the scope of formula (If) include those set out in Figure 2 as "G" ligands.
  • X 1 is C
  • X 2 is CR 5
  • X 3 is CR 6
  • X 4 is NR 7 and are referred to as formulae (Ig):
  • R 1 is a halogen.
  • R 2 is a hydrogen or methyl.
  • R 3 is a halogen.
  • R 5 is a hydrogen,
  • R 6 is a hydrogen,
  • R 7 is a hydrogen, an alkyl or a substituted alkyl. In certain embodiments, formulae (Ig) do not include the compounds where R 1 and R 3 are fluorine and R 7 is a t-butyl.
  • compositions of matter including ligands, compositions and metal-ligand complexes, that include a compound characterized by the formula (II):
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 are each independent of one another and are as described above.
  • X 1 is N or C
  • X 2 is N or CR 5
  • X 3 is N or
  • CR 6 , X 4 is N or CR 7 , provided that the heteroatom containing ring system is heteroaromatic, provided that compounds when X 1 , X 2 , X 3 and X 4 are each C, R 5 , R 6 and
  • R 7 are each H and R 1 is selected from the group consisting of t-butyl, -CMe 2 Et, -C(Et) 3 , -
  • CMe 2 Ph, -C(Ph) 3 , -Si(Et) 3 , and -Si(Ph) 3 are not included.
  • R 1 is selected from the group consisting of alkyl, naphthyl, substituted naphthyl, carbazolyl, substituted carbazolyl, phenyl, substituted phenyl, indolyl, substituted indolyl, adamantyl, substituted adamantyl, thiophenyl, substituted thiophenyl, benzofuranyl, substituted benzofuranyl, benzothioplienyl and substituted benzothiophenyl.
  • R 7 is selected from the group consisting of alkyl, naphthyl, substituted naphthyl, carbazolyl, substituted carbazolyl, phenyl, substituted phenyl, indolyl, substituted indolyl, adamantyl, substituted adamantyl, thiophenyl, substituted thiophenyl, benzofuranyl, substituted benzofuranyl, benzothiophenyl and substituted benzothiophenyl
  • R 1 is selected from the group consisting of t-butyl, naphthyl, substituted naphthyl, carbazolyl, substituted carbazolyl, phenyl and substituted phenyl and R 7 is selected from the group consisting of substituted phenyl and anthracenyl.
  • R 1 is an alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl or a substituted heteroaryl.
  • R 3 is a hydrogen, an alkyl or a substituted alkyl.
  • R 6 is an aryl or a substituted aryl.
  • R 7 is an aryl or a substituted aryl. Suitable examples of ligands within the scope of formula (Ha) include those set out in Figure 2 as "E" ligands.
  • compositions of matter including ligands, compositions and metal-ligand complexes, that include a compound characterized by the formula (III):
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , and R 11 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heteroalkyl, substituted heteroalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkoxy, aryloxy, halo, silyl, boryl, phosphino, amino, thioalkyl, thioaryl, nitro, and combinations thereof, with the exception that R 1 may not be hydrogen, optionally two or more of R 1 , R 2 , R 3 and R 4 may be joined to form a fused ring system having up to 50 atoms, not counting hydrogen atoms, and optionally two or more of R 8 , R 9 , R 10 and R 11 may be joined to form
  • X 1 is N or C
  • X 2 is O, S, N(R 5 ) n > or CR 5 , wherein n' is 0 or 1, provided that the heteroatom containing ring system is heteroaromatic, provided X and X are not both N.
  • R 1 is selected from the group consisting of t-butyl, naphthyl, substituted naphthyl, carbazolyl, substituted carbazolyl, phenyl and substituted phenyl.
  • R 1 is an alkyl, substituted alkyl, aryl or a substituted aryl.
  • R 3 is a hydrogen, alkyl or substituted alkyl.
  • R 5 is an alkyl or substituted alkyl. Suitable examples of ligands within the scope of formula (Ilia) include FI l and F12 set forth in Figure 2.
  • X 2 is S and are referred to as formulae (HIb):
  • R 1 is an alkyl or a substituted alkyl.
  • R 3 is a hydrogen, an alkyl or a substituted alkyl.
  • Suitable examples of ligands within the scope of formula (HIb) include C29 those set forth in Figure 2.
  • X is CR and are referred to as formulae (HId):
  • R 1 is an alkyl or substituted alkyl.
  • R 3 is an alkyl or substituted alkyl.
  • Suitable example of a ligand within the scope of formula (HId) includes G4 set out in Figure 2.
  • the invention provides compositions of matter, including ligands, compositions and metal-ligand complexes, that include a compound characterized by the formula (IV):
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , and R 11 are each independent of each other and are as described above.
  • R 1 is selected from the group consisting of t-butyl, naphthyl, substituted naphthyl, carbazolyl, substituted carbazolyl, phenyl and substituted phenyl.
  • R 1 is an alkyl, substituted alkyl, aryl or substituted aryl.
  • R 3 is a hydrogen, an alkyl or a substituted alkyl.
  • R 9 is a hydrogen, halogen, alkyl, substituted alkyl, or an alkoxy.
  • R 10 is a hydrogen, halogen, alkyl, or a substituted alkyl.
  • compositions of matter including ligands, compositions and metal-ligand complexes, that include a compound characterized by the formula (V):
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , and R 11 are each independent of each other and are as described above.
  • X 1 is N or C
  • X 2 is O, S, N(R 5 ) n - or CR 5 , wherein n' is 0 or 1, provided that the heteroatom containing ring system is heteroaromatic, provided when X 1 and X 2 are both N, then:
  • R 1 is t-butyl
  • R 2 is H
  • R 3 is Me
  • R 4 is H
  • R 8 , R 9 , R 11 are each H
  • R 10 is
  • R 1 is i-propyl
  • R 2 is H
  • R 3 is t-butyl
  • R 4 , R 8 , R 9 , R 10 and R 11 are each H;
  • R 1 is t-butyl
  • R 2 is H
  • R 3 is t-butyl
  • R 4 is H
  • R 8 , R 9 , R 11 are each H and R 10 is Cl;
  • R 1 is 1,1-dimethylpropyl
  • R 2 is H
  • R 3 is 1,1-dimethylpro ⁇ yl
  • R 4 , R 8 , R 9 is 1,1-dimethylpro ⁇ yl
  • R 10 and R 11 are each H;
  • R 1 is isopropylbenzyl
  • R 2 is H
  • R 3 is isopropylbenzyl
  • R 4 is H
  • R 8 , R 9 , R 11 are each H and R 10 is Cl;
  • R 1 is t-butyl
  • R 2 is H
  • R 3 is t-butyl
  • R 4 is H
  • R 8 , R 9 , R 11 are each H and R 10 is F;
  • R 1 is t-butyl
  • R 2 is H
  • R 3 is t-butyl
  • R 4 is H
  • R 8 , R 11 are each H
  • R 9 and R 10 are each F
  • R 1 is t-butyl
  • R 2 is H
  • R 3 is /-butyl
  • R 4 is H
  • R 8 , R 11 are each H
  • R 9 and R 10 are each Cl
  • R 1 is t-butyl
  • R 2 is H
  • R 3 is t-butyl
  • R 4 is H
  • R 8 , R 9 , R 11 are each H and R 10 is -CF 3 ;
  • R 1 is t-butyl
  • R 2 is H
  • R 3 is t-butyl
  • R 4 is H
  • R 8 , R 9 , R 11 are each H and R 10 is -OMe;
  • R 1 is t-butyl
  • R 2 is H
  • R 3 is t-butyl
  • R 4 is H
  • R 8 , R 11 are each H
  • R 9 and R 10 is are each Me
  • R 1 is t-butyl
  • R 2 is H
  • R 3 is -OMe
  • R 4 is H
  • R 8 , R 9 , R 11 are each H and R 10 is Cl;
  • R 1 is phenyl
  • R 2 is H
  • R 3 is t-butyl
  • R 4 is H
  • R 8 , R 9 , R 11 are each H and R 10 is Cl;
  • R 1 is t-butyl
  • R 2 is H
  • R 3 is -Me
  • R 4 is H
  • R 8 , R 9 , R 11 are each H
  • R 10 is
  • R 1 is 2,4,6-trimethylphenyl
  • R 2 is H
  • R 3 is -Me
  • R 4 is H
  • R 8 , R 9 , R 11 are each H and R 10 is Cl;
  • R 1 is 1-naphthyl
  • R 2 is H
  • R 3 is -Me
  • R 4 is H
  • R 8 , R 9 , R 11 are each H and
  • R 10 is Cl
  • R 1 is 9-anthracenyl
  • R 2 is H
  • R 3 is -Me
  • R 4 is H
  • R 8 , R 9 , R 11 are each H and R 10 is Cl;
  • R 1 is 3,5-difluorophenyl
  • R 2 is H
  • R 3 is -Me
  • R 4 is H
  • R 8 , R 9 , R 11 are each
  • R 1 is an alkyldiarylsilyl or dialkylarylsilyl
  • R 2 is H
  • R 3 is -Me
  • R 4 is H
  • R 8 is H
  • R 9 , R 11 are each H and R 10 is Cl; but
  • R 1 is selected from the group consisting of t-butyl, naphthyl, substituted naphthyl, carbazolyl, substituted carbazolyl, phenyl and substituted phenyl.
  • R 1 is selected from the group consisting of optionally substituted alkyl, heteroalkyl, aryl and heteroaryl.
  • R 1 can be selected from the group consisting of alkyl, substituted alkyl, naphthyl, substituted naphthyl, N-carbazolyl, substituted N-carbazolyl, phenyl, substituted phenyl, indolyl, substituted indolyl, adamantyl, substituted adamantyl, thiophenyl, substituted thiophenyl, benzofuranyl, substituted benzofuranyl, benzothiophenyl and substituted benzotliiophenyl.
  • R 7 is selected from the group consisting of optionally substituted alkyl, heteroalkyl, aryl and heteroaryl; more specifically, selected from the group consisting of alkyl, substituted alkyl, naphthyl, substituted naphthyl, carbazolyl, substituted carbazolyl, phenyl, substituted phenyl, indolyl, substituted indolyl, adamantyl, substituted adamantyl, thiophenyl, substituted thiophenyl, benzofuranyl, substituted benzofuranyl, benzothiophenyl and substituted benzothiophenyl.
  • the choice of particular heterocyclic ligand can have a strong influence on the catalysis of particular transformations.
  • the choice of substituent in the ligands of the invention when incorporated in a polymerization catalyst can affect catalyst activity, thermal stability, molecular weight of the product polymer, or the degree and/or kind of stereo- or regioerrors, as well as other factors known to be significant in the production of various polymers.
  • Specific ligands, metal precursors and activation techniques that are used for the production of polypropylene are specified in Tables 2C, 3 A and 3B. Additionally, specific ligands, metal precursors and activation techniques that are used for the production of low molecular weight polypropylene waxes are specified in Table 3A, examples PP3-PP7, and Table 3B. Specific ligands, metal precursors and activation techniques that are used for the production of ethlyene-1-octene copolymersare specified in Tables 3C and 3D. Specific ligands, metal precursors and activation techniques that are used for the production of polystyene are specified in Tables 3E.
  • the ligands of the invention can be prepared using known procedures, such as those described, for example, in March, Advanced Organic Chemistry, Wiley, New York 1992 (4 th Ed.), and in Katritzky et al, Comprehensive Heterocyclic Chemistry, Elsevier, New York 1984 (1 st Ed.) & 1996 (2 nd Ed.). Specifically, in some embodiments the ligands of the invention can be prepared according to the general procedures that follow.
  • the desired ligand can be combined with a metal atom, ion, compound or other metal precursor compound, and in some embodiments the present invention encompasses compositions that include any of the above-mentioned ligands in combination with an appropriate metal precursor and an optional activator.
  • the metal precursor can be an activated metal precursor, which refers to a metal precursor (described below) that has been combined or reacted with an activator (described below) prior to combination or reaction with the ancillary ligand.
  • the invention provides compositions that include such combinations of ligand and metal atom, ion, compound or precursor.
  • the ligands are combined with a metal compound or precursor and the product of such combination is not determined, if a product forms.
  • the ligand may be added to a reaction vessel at the same time as the metal or metal precursor compound along with the reactants, activators, scavengers, etc.
  • the ligand can be modified prior to addition to or after the addition of the metal precursor, e.g. through a deprotonation reaction or some other modification.
  • the metal precursor compounds can be characterized by the general formula M(L) m where M is a metal selected from the group consisting of groups 3-6 and lanthanides of the periodic table of elements and m is 1, 2, 3, 4, 5, or 6.
  • M can be selected from scandium, yttrium, titanium, zirconium, hafnium, vanadium, niobium, tantalum, chromium, molybdenum, tungsten, lanthanum, cerium, praseodymium, neodymium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium, and lutetium.
  • Each L is a ligand independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, heteroalkyl, allyl, diene, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, aryl, heteroaryl, alkoxy, aryloxy, boryl, silyl, amino, phosphino, ether, thioether, phosphine, amine, carboxylate, alkylthio, arylthio, 1,3-dionate, oxalate, carbonate, nitrate, sulphate, and combinations thereof.
  • two or more L groups are joined into a ring structure.
  • L may be ionically bonded to the metal M and, for example, L may be a non-coordinated or loosely coordinated or weakly coordinated anion (e.g., L may be selected from the group consisting of those anions described below in the conjunction with the activators). (See Marks et al., Chem. Rev. 2000, 100, 1391-1434, for a detailed discussion of these weak interactions.)
  • the metal precursors may be monomeric, dimeric or higher orders thereof.
  • the metal precursor includes a metal selected from Ti, Zr, or Hf.
  • the metal precursor includes a metal selected from Zr and Hf.
  • Suitable titanium, hafnium and zirconium precursors include, but are not limited to TiCl 4 , Ti(CH 2 Ph) 4 , Ti(CH 2 CMe 3 ) 4 , Ti(CH 2 SiMe 3 ) 4 , Ti(CH 2 Ph) 3 Cl, Ti(CH 2 CMe 3 ) 3 Cl, Ti(CH 2 SiMe 3 ) 3 Cl, Ti(CH 2 Ph) 2 Cl 2 , Ti(CH 2 CMe 3 ) 2 Cl 2 , Ti(CH 2 SiMe 3 ) 2 Cl 2 , Ti(NMe 2 ) 4 , Ti(NEt 2 ) 4 , Ti(O- i Pr) 4 , and Ti(N(SiMe 3 ) 2 ) 2 Cl 2 ; HfCl 4 , Hf(CH 2 Ph) 4 , Hf(CH 2 CMe 3 ) 4 , Hf(CH 2 SiMe 3 ) 4 , Hf(CH 2 Ph) 3 Cl, Hf(CH 2 Ph) 3 Cl
  • Lewis base adducts of these examples are also suitable as metal precursors, for example, ethers, amines, thioethers, phosphines and the like are suitable as Lewis bases.
  • Specific examples include HfCl 4 (THF) 2 , HfCl 4 (SMe 2 ) 2 and Hf(CH 2 Ph) 2 Cl 2 (OEt 2 ).
  • Activated metal precursors may be ionic or zwitterionic compounds, such as [M(CH 2 Ph) 3 + ] [B(C 6 F 5 )_ ⁇ or [M(CH 2 Ph) 3 + ] [PhCH 2 B(C 6 Fs) 3 ⁇ l where M is Zr or Hf.
  • Activated metal precursors or such ionic compounds can be prepared in the manner shown in Pelleccliia et al., Organometallics 1994, 13, 298-302; Pellecchia et al., J. Am. Chem. Soc.
  • the ligand to metal precursor compound ratio is typically in the range of about 0.01:1 to about 100:1, more specifically in the range of about 0.1:1 to about 10:1 and even more specifically about 1:1, 2:1 or 3:1.
  • this invention relates to compositions of one or more ligands and a metal precursor compound, where the compositions include two equivalents of ligand to metal precursor compound, referred to herein as the bis- ligand embodiment.
  • the other aspects there is also a bis-ligand complex embodiment, specifically, those embodiments where x is 2 in the below complexation formulae.
  • the bis-ligand composition embodiment can include two equivalents of the same phenol- heterocycle ligand or one equivalent of a first phenol-heterocycle ligand and one equivalent of a second phenol-heterocycle ligand, wherein the first and second phenol- heterocycle ligands are different from each other.
  • the ratio of first phenol-heterocycle ligand to second phenol-heterocycle ligand is not one to one, but ranging from 1 to 99 parts to 99 to 1 parts.
  • the first phenol-heterocycle ligand is a ligand of this invention and the second phenol-heterocycle ligand is otherwise known.
  • the second phenol- heterocycle ligand can be a triazole ligand, such as those disclosed in US Patent 6,933,355, incorporated herein by reference.
  • Triazole ligands that may be used as second phenol-heterocycle ligands in bis-ligand compositions (and complexes) include those characterized by the general formula:
  • R 8 , R 9 , R 10 and R 11 are selected from the same groups as R 1 , R 2 ,
  • R 3 , and R 4 defined in the various embodiments above.
  • Specific examples of ligands that may be preferably used as second phenol-heterocycle ligands in bis-ligand are shown in the various examples and figures herein. See the following for general mixed ligand systems: J. Am. Chem. Soc. 2004, 126, 10798-10799; Chem. Common. 2005, 25, 3150- 3152; and Dalton Trans. 2005, 3611-3613, each of which is incorporated herein by reference.
  • the invention relates to metal- ligand complexes.
  • the ligand (or optionally a modified ligand as discussed above) is mixed with a suitable metal precursor (and optionally other components, such as activators) prior to or simultaneously with allowing the mixture to be contacted with the reactants (e.g., monomers).
  • a metal-ligand complex may be formed, which may itself be an active catalyst or may be transformed into a catalyst upon activation.
  • the invention features metal-ligand complexes characterized by the formula (VI):
  • formulae (VI) includes those compounds having formulae (II), (Ha) and (IV) as described above, the nitrogen includes a hydrogen, and m' and x are as described above.
  • the dashed bond shown between the nitrogen atom with M depicted in formula (VI) can be dative, nonexistent, or covalent. When the bond is intended to be a dative bond, it is shown as a dashed arrow.
  • the bond between the nitrogen atom and the metal (M) may come on and off again, giving it fluxional behavior, and thus any of the formula here can be drawn without that bond.
  • compounds may include those of formula (Va) as one of the bis-ligand compounds.
  • the complex may include more than one metal (M) and one or more ligands, each independent of one another, and the ligand to metal ratio may be fractional.
  • Particular embodiments can include one or more of the following features.
  • the complex can be characterized by the formula (VII):
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X 1 , X 2 , X 3 and X 4 are as described above for compounds of formulae (I) through formulae (Ig); M and L are as described above, x is 1, 2, 3, or 4, m" is 0, 1, 2, 3, or 4 and the bond between the heteroaromatic nitrogen (N) and the metal (M) is dative or absent.
  • X 1 is C
  • X 2 is O
  • X 3 is N
  • X 4 is CR 7 and are referred to as formulae (Vila):
  • R 1 is an alkyl, substituted alkyl, aryl or a substituted aryl.
  • R is an alkyl or a substituted alkyl.
  • R 7 is an aryl or a substituted aryl.
  • R 1 is an alkyl or a substituted alkyl.
  • R 3 is an alkyl or a substituted alkyl.
  • R 7 is an aryl or a substituted aryl.
  • X 3 is CR 6 and X 4 is CR 7 and are referred to as formulae (VIIc):
  • R 1 is an alkyl, substituted alkyl, aryl, or a substituted aryl.
  • R 3 is an alkyl or a substituted alkyl.
  • R 5 is an alkyl or a substituted alkyl.
  • R 6 is an aryl or a substituted aryl.
  • R 7 is an aryl or a substituted aryl.
  • Suitable examples of ligands within the scope of formula (VIIc) include those set out in Table 3.
  • X 1 is C
  • X 2 is S
  • X 3 is CR 6
  • X 4 is CR 7 and are referred to as formulae (VIId):
  • R 1 is an aryl, substituted aryl, alkyl or a substituted alkyl.
  • R 3 is an alkyl or a substituted alkyl.
  • R 6 is a hydrogen.
  • R 7 is bromide, phenyl, substituted phenyl, naphthyl, substituted naphthyl, anthracenyl, substituted anthracenyl, or a hydrogen.
  • ligands within the scope of formula (VIId) include those set out in Table 5.
  • X 1 is C
  • X 2 is
  • R 1 is an aryl or a substituted aryl.
  • R 3 is a hydrogen, an alkyl or a substituted alkyl.
  • R 5 is a hydrogen.
  • R 7 is an aryl or a substituted aryl.
  • R 1 is an aryl or substituted aryl.
  • R 3 is an alkyl or substituted alkyl.
  • R 5 is a hydrogen.
  • R 6 is a hydrogen.
  • R 7 is an alkyl or phenyl.
  • Suitable examples of ligands within the scope of formula (VIIf) include those set out in Table 7. [00216] In an seventh embodiment for complexes having formula (VII), X 1 is C,
  • X 2 is CR 5
  • X 3 is CR 6
  • X 4 is NR 7 and are referred to as formulae (VIIg):
  • R 1 is a halogen.
  • R 2 is a hydrogen or methyl.
  • R 3 is a halogen.
  • R 5 is a hydrogen.
  • R is a hydrogen,
  • R 7 is a hydrogen, an alkyl or a substituted alkyl. In certain embodiments, formulae (VIIg) do not include the compounds where R 1 and R 3 are fluorine and R 7 is a t-butyl.
  • the invention features metal-ligand complexes characterized by the formula (VIII):
  • R 1 , R 2 , R 3 , R 4 R 5 , R 6 , R 7 , X 1 , X 2 , X 3 and X 4 are as described above for compounds of formulae (II) and (Ha), M and L are as described above, x is 1 or 2 and m" is 0, 1, 2, 3, or 4.
  • X 3 is CR 6 and X 4 is CR 7 and are referred to as formulae (Villa):
  • R 1 is an alkyl, substituted alkyl, aryl, or a substituted aryl.
  • R 3 is a hydrogen, an alkyl or a substituted alkyl.
  • R 6 is an aryl or a substituted aryl.
  • R 7 is an aryl or a substituted aryl.
  • Suitable examples of ligands within the scope of formula (Villa) include those set out in Table 4.
  • the invention features metal-ligand complexes characterized by the formula (IX):
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , X1 and X 2 are as described above for compounds of formulae (III) through formulae (HId), M and L are as described above, x is 1, 2, 3, or 4 and m" is 0, 1, 2, 3, or 4 and the bond between N and the metal (M) is dative or absent.
  • R 1 is an alkyl, substituted alkyl, aryl or a substituted aryl.
  • R 3 is a hydrogen, alkyl or substituted alkyl.
  • R 5 is an alkyl or substituted alkyl.
  • Suitable examples of ligands within the scope of formula (IXa) include those set forth in Table 9.
  • X 2 is S and are referred to as formulae (IXb);
  • R 1 is an alkyl or a substituted alkyl.
  • R 3 is a hydrogen, an alkyl or a substituted alkyl.
  • Suitable examples of ligands within the scope of formula (IXb) include those set forth in Table 11.
  • X 2 is CR 5 and are referred to as formulae (IXd):
  • R 1 is an alkyl or substituted alkyl.
  • R is an alkyl or substituted alkyl.
  • Suitable examples of ligands within the scope of formula (IXd) include those set out in Table 13.
  • the invention features metal-ligand complexes characterized by the formula :
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , X 1 and X 2 are as described above for compounds of formulae (IV) and (IVa), M and are as described above, x is 1 or 2 and m" is ⁇ , 1, 2, 3, or 4.
  • R 1 is an alkyl, substituted alkyl, aryl or substituted aryl.
  • R 3 is a hydrogen, an alkyl or a substituted alkyl.
  • R 9 is a hydrogen, halogen, alkyl, substituted alkyl, or an alkoxy.
  • R 10 is a hydrogen, halogen, alkyl, or a substituted alkyl.
  • the invention features metal-ligand complexes characterized by the formula (XI):
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , X 1 and X 2 are as described above for compounds of formulae (V), M and L are as described above, x is 1, 2, 3, or 4 and m" is 0, 1, 2, 3, or 4 and the bond between N and the metal (M) is dative or absent.
  • the ligands, complexes or catalysts may be supported on organic or inorganic supports. Suitable supports include silicas, aluminas, clays, zeolites, magnesium chloride, polystyrenes, substituted polystyrenes and the like. Polymeric supports may be cross-linked or not.
  • the ligands, complexes or catalysts may be supported on supports known to those of skill in the art. See for example, Severn et al. Chem. Rev. 2005, 105, 4073-4147, particularly pages 4115-4117; Hlatky, Chem. Rev. 2000, 100, 1347-1376 and Fink et al., Chem. Rev. 2000, 100, 1377-1390, each of which is incorporated herein by reference, including the references cited therein.
  • the compositions, complexes and/or catalysts may be contacted with an activator (described below) before or after contact with the support; alternatively, the support may be contacted with the activator prior to contact with the composition, complex or catalyst.
  • the catalysts of this invention may be combined with other catalysts in a single reactor and/or employed in a series of reactors (parallel or serial) in order to form blends of polymer products.
  • x is 2 in any of formulae (VII), (Vila), (VIIb), (VIIc), (VIId), (VIIe), (VIIf), (VIIg), (VIIh), (VIIi), (VIIj), (VIII), (Villa), (IX), (IXa), (IXb), (IXc), (IXd), (X), (Xa), and/or (XI).
  • the bis-ligand complex embodiments include two equivalents of the same phenol-heterocycle ligand or one equivalent of a first phenol- heterocycle ligand and one equivalent of a second phenol-heterocycle ligand, wherein the first and second phenol-heterocycle ligands are different from each other.
  • the first phenol-heterocycle ligand is a ligand in accord with this invention and the second phenol-heterocycle ligand is otherwise known.
  • the second phenol-heterocycle ligand can be a triazole ligand, such as those disclosed in US Patent 6,933,355, incorporated herein by reference.
  • use of a triazole ligand as the second phenol-heterocycle ligand in a bis-ligand complexes in accord with formula (VII) is characterized by the general formula:
  • a bis-ligand complex can be characterized by the general formula:
  • each R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 are the same or different and are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heteroalkyl, substituted heteroalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkoxy, aryloxy, halo, silyl, boryl, phosphino, amino, thioalkyl, thioaryl, nitro, and combinations thereof, with the exception that R 1 may not be hydrogen, optionally two or more of R 1 , R 2 , R 3 and R 4 on the same ring in the formula may be joined to form a fused ring system having up to 50 atoms, not counting hydrogen atoms, and optionally two or more of R 5 , R 6 and R 7 on the same ring in
  • X 1 is N or C
  • X 2 is O, S, N(R 5 ) n' or CR 5
  • X 3 is O, S, N(R 6 ) n - or CR 6
  • X 4 is O, S, N(R 7 ) n »> or CR 7 , wherein each n', n", and n'" are each independently 0 or 1, provided that the heteroatom containing ring system is heteroaromatic
  • X 5 is N or C
  • X 6 is O, S, N(R 5 ) n - or CR 5
  • X 7 is O, S, N(R 6 ) n - or CR 6
  • X 8 is O, S, N(R 7 ) n > " or CR 7 , wherein each n', n", and n'" are each independently 0 or 1 provided that the heteroatom containing ring system is heteroaromatic.
  • the atoms in the X 1 , X 2 , X 3 /X 4 , N ring are different from the atoms in the X 5 , X 6 , X 7 , X 8 , N ring in the selection of the C, N, O or S atom, such that at least, either X 1 and X 5 are different or X 2 and X 6 are different or X 3 and X 7 are different or X 4 and X 8 are different.
  • X 1 and X 5 are different or X 2 and X 6 are different or X 3 and X 7 are different or X 4 and X 8 are different.
  • more than these particular X groups might be different from each other.
  • Certain embodiments include, triazoles, where combinations of X 5 , X 6 ; X 5 , X 7 ; or X 5 , X 8 are both N (meaning that the atom in the ring is N, but the R groups are as specified herein);
  • 2-benzotriazoles where X and X are both N; X , X are carbon atoms of benzo-ring fused to triazole; 1-benzotriazoles, X 5 and X 8 are both N, X 6 , X 7 are carbon atoms of benzo-ring fused to triazole); and tetrazoles, where X 5 is N, and 2 of X 6 ; X 7 ; or X 8 are N.
  • M is a metal selected from the group consisting of groups 3 through 6 of the periodic table elements and lanthanides; wherein each L is independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, heteroalkyl, allyl, diene, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, aryl, heteroaryl, alkoxy, aryloxy, boryl, silyl, amino, phosphino, ether, thioether, phosphine, amine, carboxylate, alkylthio, arylthio, 1,3-dionate, oxalate, carbonate, nitrate, sulphate, and combinations thereof; m" is 0, 1, 2, or 3; and the bond between the heteroaromatic nitrogens (N) and the metal (M) is dative or absent.
  • the metal-ligand complexes and compositions described herein are active catalysts typically in combination with a suitable activator, combination of activators, activating technique or activating technique, although some of the ligand-metal complexes may be active without an activator or activating technique depending on the ligand-metal complex and on the process being catalyzed.
  • the activator(s) may comprise alumoxanes, Lewis acids, Bronsted acids, compatible non-interfering activators and combinations of the foregoing.
  • Suitable ion forming compounds useful as an activator in one embodiment comprise a cation that is a Bronsted acid capable of donating a proton, and an inert, compatible, non-interfering, anion, A " .
  • Suitable anions include, but are not limited to, those containing a single coordination complex comprising a charge-bearing metal or metalloid core.
  • the anion should be sufficiently labile to be displaced by olefmic, diolefinic and unsaturated compounds or other neutral Lewis bases such as ethers or nitriles.
  • Suitable metals include, but are not limited to, aluminum, gold and platinum.
  • Suitable metalloids include, but are not limited to, boron, phosphorus, and silicon.
  • Compounds containing anions that comprise coordination complexes containing a single metal or metalloid atom are well known and many, particularly such compounds containing a single boron atom in the anion portion, are available commercially.
  • activators may be represented by the following general formula: (L*— H) d + (A d -) wherein L* is a neutral Lewis base; (L* — H) + is a Bronsted acid; A d" is a non-interfering, compatible anion having a charge of d-, and d is an integer from 1 to 3.
  • d is one, i.e., the counter ion has a single negative charge and corresponds to the formula A ' .
  • Activators comprising boron or aluminum can be represented by the following general formula:
  • L* is as previously defined; M 55 is boron or aluminum; and Q is a fluorinated C 1-20 hydrocarbyl group.
  • Q is independently selected from the group consisting of fluorinated aryl group, such as a pentafluorophenyl group (i.e., a C 6 F 5 group) or a 3,5-bis(CF 3 ) 2 C 6 H 3 group.
  • Specific (L*— H) + cations are N,N-dialkylanilinium cations, such as HNMe 2 Ph + , substituted N,N-dialkylanilinium cations, such as (4-nBu- C 6 H 4 )NH(n-C 6 H 13 ) 2 + and (4-nBu-C 6 H 4 )NH(n-C 10 H 21 ) 2 + and HNMe(C 18 H 37 ) 2 + .
  • Specific examples of anions are tetrakis(3,5-bis(trifluoromethyl)phenyl)borate and tetrakis(pentafluorophenyl)borate.
  • the specific activator is PhNMe 2 H + B(C 6 F 5 ) 4 -.
  • Suitable ion forming activators comprise a salt of a cationic oxidizing agent and a non-interfering, compatible anion represented by the formula:
  • Ox e+ is a cationic oxidizing agent having a charge of e+; e is an integer from 1 to 3; and A d ⁇ , and d are as previously defined.
  • cationic oxidizing agents include: ferrocenium, hydrocarbyl-substituted ferrocenium, Ag + , or Pb +2 .
  • Specific embodiments of A d" are those anions previously defined with respect to the Bronsted acid containing activating cocatalysts, especially tetrakis(pentafluorophenyl)borate.
  • Another suitable ion forming, activating cocatalyst comprises a compound that is a salt of a carbenium ion or silyl cation and a non-interfering, compatible anion represented by the formula: ⁇ + A- wherein: ⁇ + is a C 1-1O0 carbenium ion or silyl cation; and A- is as previously defined.
  • a preferred carbenium ion is the trityl cation, i.e. triphenylcarbenium.
  • the silyl cation may be characterized by the formula Z 4 Z 5 Z 6 Si + cation, where each of Z 4 , Z 5 , and Z 6 is independently selected from the group consisting of hydrogen, halogen, and optionally substituted alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, heteroaryl, alkoxyl, aryloxyl, silyl, boryl, phosphino, amino, mercapto, alkylthio, arylthio, and combinations thereof.
  • a specified activator is Ph 3 C + B(C 6 F 5 ) 4 -.
  • Suitable activating cocatalysts comprise a compound that is a salt, which is represented by the formula (A* +a ) b (Z*J* j ) "C d wherein A* is a cation of charge +a; Z* is an anion group of from 1 to 50, specifically 1 to 30 atoms, not counting hydrogen atoms, further containing two or more Lewis base sites; J* independently each occurrence is a Lewis acid coordinated to at least one Lewis base site of Z*, and optionally two or more such J* groups may be joined together in a moiety having multiple Lewis acidic functionality; j is a number form 2 to 12; and a, b, c, and d are integers from 1 to 3, with the proviso that a x b is equal to c x d.
  • the anion portion of these activating cocatalysts may be characterized by the formula ((C 6 F 5 ) 3 M""-LN-M""(C 6 F 5 ) 3 ) " where M"" is boron or aluminum and LN is a linking group, which is specifically selected from the group consisting of cyanide, azide, dicyanamide and imidazolide.
  • the cation portion is specifically a quaternary amine. See, e.g., LaPointe, et ah, J. Am. Chan. Soc. 2000, 122, 9560-9561, which is incorporated herein by reference.
  • suitable activators include Lewis acids, such as those selected from the group consisting of tris(aryl)boranes, tris(substituted aryl)boranes, tris(aryl)alanes, tris(substituted aryl)alanes, including activators such as tris(pentafluorophenyl)borane.
  • Lewis acids such as those selected from the group consisting of tris(aryl)boranes, tris(substituted aryl)boranes, tris(aryl)alanes, tris(substituted aryl)alanes, including activators such as tris(pentafluorophenyl)borane.
  • Other useful ion forming Lewis acids include those having two or more Lewis acidic sites, such as those described in WO 99/06413 or Piers, et al, J. Am. Chem. Soc, 1999, 121, 3244-3245, both of which are incorporated herein by reference.
  • the group of Lewis acid activators is within the group of ion forming activators (although 1 exceptions to this general rule can be found) and the group tends to exclude the group 13 reagents listed below. Combinations of ion forming activators maybe used.
  • Other general activators or compounds useful in a polymerization reaction may be used. These compounds may be activators in some contexts, but may also serve other functions in the polymerization system, such as alkylating a metal center or scavenging impurities. These compounds are within the general definition of "activator,” but are not considered herein to be ion-forming activators.
  • G 13 is selected from the group consisting of B, Al, Ga, In and combinations thereof, p is 0, 1 or 2
  • each R 50 is independently selected from the group consisting of hydrogen, halogen, and optionally substituted alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, heteroaryl, and combinations thereof
  • each D is independently selected from the group consisting of halogen, hydrogen, alkoxy, aryloxy, amino, mercapto, alkylthio, arylthio, phosphino and combinations thereof.
  • the group 13 activator is an oligomeric or polymeric alumoxane compound, such as methylalumoxane and the known modifications thereof. See, for example, Barron, "Alkylalumoxanes, Synthesis, Structure and Reactivity", pp. 33-67 in Metallocene-Based Polyolefins: Preparation, Properties and Technology, J. Schiers and W. Kaminsky (eds.), Wiley Series in Polymer Science, John Wiley & Sons Ltd., Chichester, England, 2000, and references cited therein.
  • a divalent metal reagent may be used that is defined by the general formula M'R 50 2-P' D P' and p' is 0 or 1 in this embodiment and R 50 and D are as defined above.
  • M' is the metal and is selected from the group consisting of Mg, Ca, Sr, Ba, Zn, Cd and combinations thereof.
  • an alkali metal reagent may be used that is defined by the general formula M"'R 50 and in this embodiment R 50 is as defined above.
  • M' v is the alkali metal and is selected from the group consisting of Li, Na, K, Rb, Cs and combinations thereof.
  • hydrogen and/or silanes may be used in the catalytic composition or added to the polymerization system. Silanes may be characterized by the formula SiR 5 VqDq where R 50 is defined as above, q is 1, 2, 3 or 4 and D is as defined above, with the proviso that there is at least one D that is a hydrogen.
  • the molar ratio of metal: activator (whether a composition or complex is employed as a catalyst) employed specifically ranges from 1:10,000 to 100:1, more specifically from 1:5000 to 10:1, most specifically from 1:10 to 1:1.
  • mixtures of the above compounds are used, particularly a combination of a group 13 reagent and an ion-forming activator.
  • the molar ratio of group 13 reagent to ion-forming activator is specifically from 1:10,000 to 1000:1, more specifically from 1:5000 to 100:1, most specifically from 1:100 to 10:1.
  • the ion forming activators are combined with a group 13 reagent.
  • Another embodiment is a combination of the above compounds having about 1 equivalent of an optionally substituted N,N-dialkylanilinium tetrakis(pentafluorophenyl) borate, and 5-30 equivalents of a group 13 reagent. In some embodiments from about 30 to 2000 equivalents of an oligomeric or polymeric alumoxane activator, such as a modified alumoxane (e.g., alkylalumoxane), can be used.
  • an oligomeric or polymeric alumoxane activator such as a modified alumoxane (e.g., alkylalumoxane)
  • the ligand or bis-ligand combination will be mixed with a suitable metal precursor compound prior to or simultaneous with allowing the mixture to be contacted to the reactants.
  • a metal-ligand complex may be formed, which may be a catalyst.
  • the ligand or ligand composition can be combined with an activated metal precursor, as described herein.
  • the catalysts of the invention may be combeined withother catalysts to make bi-modal polymer products; and here the catalysts may be combined together in solution and/or on a solid support.
  • the ligands, compositions, complexes and/or catalysts of the invention can be used to catalyze a variety of transformations, including, for example, oxidation, reduction, hydrogenation, hydrosilylation, hydrocyanation, hydroformylation, polymerization, carbonylation, isomerization, metathesis, carbon-hydrogen activation, carbon-halogen activation, cross-coupling, Friedel-Crafts acylation and alkylation, hydration, Diels-Alder reactions, Baeyer-Villiger reactions, and other transformations.
  • transformations including, for example, oxidation, reduction, hydrogenation, hydrosilylation, hydrocyanation, hydroformylation, polymerization, carbonylation, isomerization, metathesis, carbon-hydrogen activation, carbon-halogen activation, cross-coupling, Friedel-Crafts acylation and alkylation, hydration, Diels-Alder reactions, Baeyer-Villiger reactions, and other transformations.
  • compositions, complexes and/or catalysts according to the invention are particularly effective at polymerizing ethylene or ⁇ -olefins (such as propylene, 1-butene, 1-pentene, 1-hexene, 1-heptene, 1-octene, 1-decene and styrene), copolymerizing ethylene with ⁇ -olefins (such as propylene, 1-butene, 1-pentene, 1-hexene, 1-heptene, 1-octene, and styrene), copolymerizing ethylene with 1,1-disubstituted olefins (such as isobutylene), or copolymerizing ethylene, propylene and a diene monomer suitable for production of EPDM (Ethylene-Propylene-Diene Monomer) synthetic rubbers.
  • ⁇ -olefins such as propylene, 1-butene, 1-pentene, 1-hexene, 1-hep
  • metal-ligand compositions and complexes containing zirconium or hafnium may be useful in the polymerization of propylene to form isotactic polypropylene or in the copolymerization of ethylene and one or more ⁇ -olefins, as noted above.
  • vanadium and chromium compositions and/or complexes according to the invention may be useful in, for example, the polymerization of ethylene.
  • compositions, complexes and/or catalysts according to the invention may also polymerize monomers that have polar functionalities in homopolymerizations or copolymerizations and/or homopolymerize 1,1- and 1,2-disubstituted olefins.
  • diolefins in combination with ethylene and/or ⁇ -olefins or 1,1- and 1,2-disubstituted olefins may be copolymerized.
  • catalysts incorporating the ligands, compositions and/or complexes of the present invention exhibit high catalytic activity in the polymerization of such ⁇ -olefins, including at high temperatures.
  • monomers useful herein may be olefinically unsaturated monomers having from 2 to 20 carbon atoms either alone or in combination.
  • monomers may include olefins (including cyclic olefins), diolefins and unsaturated monomers including ethylene and C 3 to C 20 ⁇ -olefins such as propylene, 1-butene, 1- hexene, 1-octene, 4-methyl-l-pentene, 1-norbornene, styrene and mixtures thereof; additionally, 1,1-disubstituted olefins, such as isobutylene, 2-methyl- 1-butene, 2-methyl- 1-pentene, 2-ethyl-l-pentene, 2-methyl- 1-hexene, 3-trimethylsilyl-2-methyl-l-propene, ⁇ - methyl-styrene, either alone or with other monomers such as ethylene or C 3 to C 20 ⁇
  • the ⁇ - olefins listed above may be polymerized in a stereospecific manner - for example, as in the generation of isotactic or syndiotactic or hemiisotactic polypropylene. Additionally the ⁇ -olefins may be polymerized to produce a polymer with differing tacticity sequences within the polymer chain, such as polypropylene containing atactic and isotactic sequences within the same polymer chain.
  • Diolefins generally comprise 1,3-dienes such as (butadiene), substituted 1,3-dienes (such as isoprene) and other substituted 1,3-dienes, with the term substituted referring to the same types of substituents referred to above in the definition section.
  • Diolefins also comprise 1,5-dienes and other non-conjugated dienes, such as ethylidene-norbornene, 1,4-hexadiene, dicyclopentadiene and other dienes used in the manufacture of EPDM synthetic rubbers.
  • the styrene monomers may be unsubstir ⁇ ted or substituted at one or more positions on the aryl ring.
  • the use of diolefins in this invention is typically in conjunction with another monomer that is not a diolefin.
  • acetylenically unsaturated monomers may be employed.
  • the catalysts of the present invention are active for certain monomers, particularly ethylene and/or styfene.
  • the catalysts of the present invention may provide lower comonomer incorporation in the presence of a comonomer, making these catalysts particularly useful for certain polymerization reactions where low co-monomer incorporation is desired.
  • particular catalysts of the present invention co-polymerize ethylene and styrene (or substituted styrenes), forming ethylene-styrene copolymers.
  • the catalysts of this invention are useful to polymerize a vinylidene aromatic monomer in a solution polymerization process conducted at a temperature greater than or equal to 100°C.
  • Polymers that can be prepared according to the present invention include ethylene copolymers with at least one C 3 -C 20 ⁇ -olefin, particularly propylene, 1-butene, 1-hexene, 4-methyl-l-pentene and 1-octene.
  • the copolymers of ethylene with at least one C 3 -C 20 ⁇ -olefin comprise from about 0.1 mol.% ⁇ -olefin to about 50 mol.% ⁇ -olefin, more specifically from about 0.2 mol.% ⁇ -olefin to about 50 mol.% ⁇ -olefin and still more specifically from about 2 mol.% ⁇ -olefm to about 30 mol.% higher olefin.
  • product copolymers may include those of ethylene and a comonomer selected from the group consisting of propylene, 1-butene, 1- hexene, and 1-octene comprise from about 0.2 to about 30 mol.% comonomer, more specifically from about 1 to about 20 mol. % comonomer.
  • ethylene copolymers with at least one C 3 -C 20 ⁇ -olefin can be produced having a high molecular weight (e.g., greater than about 50,000, more specifically greater than about 150,000) in a solution process at a temperature of greater than about 100 °C, more specifically greater than about 130 °C.
  • ethylene copolymers with at least one C 3 -C 20 ⁇ -olefin can be produced with a low molecular weight (e.g., less than about 50,000, more specifically, less than about 40,000, and even more specifically less than about 30,000).
  • the ligands, compositions, complexes, and/or catalysts of the invention may also be used to catalyze other (i.e., non-polymerization) transformations.
  • Examples of asymmetric or enantioselective reactions catalyzed by chiral Group 4 catalysts include olefin hydrogenation, olefin epoxidation, olefin isomerization, olefin-pyridine coupling, imine hydrogenation, aldol reactions, imino aldol reactions, epoxidation of allylic alcohols, alkylation of aldehydes, alkylation of imines, Diels-Alder reactions, Baeyer- Villiger reactions, hydroamination/cyclization of amino-alkenes, pinacol coupling of aldehydes, and hydrosilation of imines, ketones, and olefins.
  • the complexes and catalysts of the invention may be chiral.
  • substantially diastereomerically pure or substantially enantiomerically pure complexes may be useful for stereoselective, asymmetric, enantioselective, or diastereoselective reactions or transformations.
  • substantially enantiomerically- or diastereomerically-pure complexes, ligand-metal compositions, and catalysts according to the invention may be used as asymmetric catalysts for a range of reactions, including polymerization reactions and other (non-polymerization) reactions, including many reactions useful in organic synthesis
  • catalysts incorporating the compositions and complexes of the invention may be used to catalyze the asymmetric production of reaction products with enantiomeric excess (ee) or diastereomeric excess (de) of greater than 90% or greater than 99%.
  • ee enantiomeric excess
  • de diastereomeric excess
  • Single enantiomers of a chiral product can be prepared by a variety of techniques, including the resolution of racemates, or the use of substantially enantiomerically pure starting materials from the chiral pool of natural products, but for large scale synthesis the use of enantioselective catalysis is often the most attractive, and most economical, choice. See, e.g., Blaser et ah, "Enantioselective Synthesis", pp. 1131-1149, in Applied Homogeneous Catalysis with Organometallic Compounds, Vol. 3, Cornils, B., & Herrmann, W.
  • novel products such as polymers, copolymers or interpolymers, may be formed having unique physical and/or melt flow properties.
  • Such novel polymers can be employed alone or with other polymers in a blend to form products that may be molded, cast, extruded or spun.
  • End uses for the polymers made with the catalysts of this invention include films for packaging, trash bags, bottles, containers, foams, coatings, insulating devices and household items.
  • functionalized polymers are useful as solid supports for organometallic or chemical synthesis processes.
  • the ⁇ -olefms listed above may be polymerized in a stereoselective manner to produce a substantially stereoregular polymer product (that is, a polymer product that is detectably enriched in m or r dyads (as determined, e.g., by 13 C NMR) as compared to a corresponding atactic material), as in the generation of isotactic, syndiotactic or hem ⁇ sotactic poly- ⁇ -olefins.
  • a substantially stereoregular polymer product that is, a polymer product that is detectably enriched in m or r dyads (as determined, e.g., by 13 C NMR) as compared to a corresponding atactic material
  • isotactic, syndiotactic or hem ⁇ sotactic poly- ⁇ -olefins for example, in some embodiments 1- butene may be polymerized into isotactic poly-1-
  • the ⁇ -olefins may be polymerized to produce a polymer with differing tacticity sequences within the polymer chain, such as polypropylene containing atactic and isotactic sequences within the same polymer chain.
  • the stereoregularity may be interrupted by stereoerrors, in particular isolated stereoerrors, which is an indication of enantiomorphic side control.
  • the isotactic polypropylene may include regioerrors as described in the literature (see, e.g., Resconi et al., Chem. Rev. 2000, 100, 1253-1345).
  • isotactic polypropylene can be produced having a narrow polydispersity (e.g., less than about 3.0 and more specifically less than 2.5) combined with a high molecular weight (e.g., greater than about 50,000, more specifically greater than about 100,000, even more specifically greater than about 150,000, and even more specifically greater than about 500,000) in a solution polymerization process at a temperature of greater than about 100°C.
  • narrow polydispersity e.g., less than about 3.0 and more specifically less than 2.5
  • a high molecular weight e.g., greater than about 50,000, more specifically greater than about 100,000, even more specifically greater than about 150,000, and even more specifically greater than about 500,000
  • isotactic polypropylene can be produced with a low molecular weight (e.g., less than about 30,000, more specifically less than about 15,000, and even more specifically less than about 5,000).
  • broader polydispersities can be obtained for the isotactic polypropylene or other polymers (e.g., copolymers of ethylene and ⁇ -olefins as discussed in more detail below) produced according to the invention.
  • the polymerization conditions are described herein, producing isotactic polypropylene with a crystallinity index of between about 0.35 and about 0.95, more specifically between about 0.65 and 0.95.
  • the crystallinity index is determined using FTIR as is known to those of skill in the art and calibrated based on a relative scale.
  • the crystallinity index value can be determined using commercially available FTIR equipment (such as a Bruker Equinox 55 with an IR Scope II in reflection mode using Pike MappIR software).
  • the crystallinity index is obtained from the ratio of band heights at 995 cm "1 and 972 cm '1 .
  • Atactic polypropylene has a ratio of band heights or crystallinity index of 0.2.' Greater than 98% isotactic polypropylene has a crystallinity index ratio of greater than 0.95. Generally, the amount of error in crystallinity index measurements is ⁇ 0.05.
  • Polymer blends of various compositions show a linear relationship between % isotacticity and crystallinity index. See, for example, J. P. Luongo, J. Appl. Polym. Sci. 1960, 3, 302-309 and T. Sundell, et al, Polymer 1996, 37, 3227-3231, each of which is incorporated herein by reference.
  • isotacticity can also be represented by percent pentads (%mmmm) as determined by 13 C NMR spectroscopy.
  • Proton decoupled 13 C NMR spectroscopy can be performed using commercially available equipment (such as a Bruker 300 MHz at 100°C probe temperature) to determine the degree of tacticity as %mmmm pentads (for assignment of 13 C signals see the review H.H. Brintzinger et al., Angew. Chem. Int. Ed. Eng. 1995, 34, 1143, which is incorporated herein by reference; and Resconi, Chem. Rev. 2000, 100, 1253-1345 and Gibson et al., Chem Rev.
  • a 15-30 mg polymer sample is dissolved in a 1:1 mixture of C 2 D 2 Cl 4 and C 2 Cl 4 by heating the sample to ca. 100°C.
  • the %mmmm is determined by the ratio of peak integral from 23.5 to 21.5 ppm and peak integral 23.5 to 19 ppm (in the absence of significant chain end regio- irregularity signals in this region).
  • Proton decoupled C NMR spectroscopy can be also performed to determine the frequency of and nature of stereoerrors and regioerrors.
  • the melting point of the crystalline polypropylene is generally in the range of from about 115°C to about 165°C, more specifically between about 120°C and 155°C, and in some embodiments specifically above about 15O°C. Melting points are determined by differential scanning calorimetry, as is known in the art (see also the example section, herein).
  • the total styrene content of the polymer products includes both the styrene incorporated in the ethylene-styrene copolymer and any background homopolystyrene (PS) in the product sample.
  • Tacticity determination for polystyrene samples are determined using C NMR. High temperature NMR spectra are recorded on a Bruker 300 MHz spectrometer. 13 C chemical shifts (75.47 MHz) are referenced relative to tetrachloro-ethane-d2 solvent peaks. Polymer sample concentrations are 100-200 mg/ml.
  • Tacticity of styrene polymers is determined using the 144-147 ppm region of the 13 C NMR spectrum (phenyl C(I)), see NMR and Macromolecules, Randall Ed., Harwood et g[. Ch. 13: Polystyrene and Epimerized Isotactic Polystyrenes (1983). [00270] The ratio of 1-octene to ethylene incorporated in the ethylene-octene copolymer products was determined by FTIR.
  • FTIR FTIR was performed on a Bruker Equinox 55 +IR Scope II in reflection mode using a Pike MappIR accessory with 16 scans.
  • the ratio of 1-octene to ethylene incorporation was represented as the weight % (wt. %) of 1- octene incorporated in the polymer (wt. % 1-octene).
  • Wt. % 1-octene was obtained from ratio of band heights at 1378 cm -1 and 4335 cm -1 . This method was calibrated using a set of ethylene/1 -octene copolymers with a range of known wt. % 1-octene content.
  • Novel polymers, copolymers or interpolymers may be formed having unique physical and/or melt flow properties.
  • Polymers that can be prepared according to the present invention include copolymers of ethylene and one or more ⁇ -olefins, such as copolymers of ethylene with at least one C 4 -C 20 ⁇ -olefm, such as 1-butene, 1-hexene, 4- methyl-1-pentene, 1-octene or styrene.
  • the techniques described herein can be used to prepare propylene copolymers with at least one C 4 -C 20 ⁇ -olef ⁇ n.
  • the copolymers of ethylene or propylene with at least one C 4 -C 20 ⁇ -olefm comprise from about 0.01 mol.% higher olefin to about 50 mol.% higher olefin, more specifically from about 0.1 mol.% higher olefin to about 50 mol.% higher olefin and still more specifically from about 1 mol.% higher olefin to about 30 mol.% higher olefin.
  • crystalline copolymers include those of ethylene or propylene and a comonomer selected from the group consisting of ethylene, 1-butene, 1-hexene, 1-octene and styrene comprise from about 0.1 to about 50 mol.% comonomer, more specifically from about 1 to about 20 mol. % comonomer, even more specifically from about 2 to about 15 mol. % comonomer and most specifically from about 5 to about 12 mol. % comonomer.
  • novel polymers disclosed herein can be employed alone or with other natural or synthetic polymers in a blend.
  • Such other natural or synthetic polymers can be polyethylene (including linear low density polyethylene, low density polyethylene, high density polyethylene, etc.), atactic polypropylene, nylon, EPDM, ethylene-propylene elastomer copolymers, polystyrene (including syndiotactic polystyrene), ethylene-styrene copolymers and terpolymers of ethylene-styrene and other C 3 -C 20 olefins (such as propylene).
  • Polymerization is carried out under polymerization conditions, including temperatures of from -100°C to 300°C and pressures from atmospheric to 3000 atmospheres.
  • Suspension, solution, slurry, gas phase or high-pressure polymerization processes may be employed with the catalysts and compounds of this invention. Such processes can be run in a batch, semi-batch or continuous mode. Examples of such processes are well known in the art.
  • a support for the catalyst may be employed, which may be inorganic (such as alumina, magnesium chloride or silica) or organic (such as a polymer or cross-linked polymer). Methods for the preparation of supported catalysts are known in the art. Slurry, suspension, gas phase and high-pressure processes as known to those skilled in the art may also be used with supported catalysts of the invention.
  • additives that are useful in a polymerization reaction may be employed, such as scavengers, promoters, modifiers and/or chain transfer agents, such as hydrogen, aluminum alkyls and/or silanes.
  • catalytic performance can be determined a number of different ways, as those of skill in the art will appreciate. Catalytic performance can be determined by the yield of polymer obtained per mole of metal complex, which in some contexts may be considered to be activity. The examples provide data for these comparisons.
  • a solution process is specified for certain benefits, with the solution process being run at a temperature above 90°C, more specifically at a temperature above 100°C, further more specifically at a temperature above HO°C and even further more specifically at a temperature above 13O°C.
  • Suitable solvents for polymerization are non-coordinating, inert liquids.
  • Examples include straight and branched-chain hydrocarbons such as isobutane, butane, pentane, isopentane, hexane, isohexane, heptane, octane, Isopar-E® and mixtures thereof; cyclic and alicyclic hydrocarbons such as cyclohexane, cycloheptane, methylcyclohexane, methylcycloheptane, and mixtures thereof; perhalogenated hydrocarbons such as perfluorinated C 4-10 alkanes, chlorobenzene, and aromatic and alkyl substituted aromatic compounds such as benzene, toluene, mesitylene, and xylene.
  • straight and branched-chain hydrocarbons such as isobutane, butane, pentane, isopentane, hexane, isohexane, heptane, octane, Isopar-E
  • Suitable solvents also include liquid olefins which may act as monomers or comonomers including ethylene, propylene, 1-butene, butadiene, cyclopentene, 1-hexene, 1-pentene, 3 -methyl- 1-pentene, 4-methyl-l-pentene, 1,4-hexadiene, 1-octene, 1-decene, isobutylene, styrene, divinylbenzene, allylbenzene, and vinyltoluene (including all isomers alone or in admixture). Mixtures of the foregoing are also suitable.
  • a solution process is specified for crystalline polypropylene production.
  • the solution process to prepare isotactic polypropylene comprises adding a catalyst and propylene monomer to a reactor and subjecting the contents to polymerization conditions.
  • the ligands, metal-ligand complexes and compositions of this invention can be prepared and tested for catalytic activity in one or more of the above reactions in a combinatorial fashion.
  • Combinatorial chemistry generally involves the parallel or rapid serial synthesis and/or screening or characterization of compounds and compositions of matter.
  • U.S. Patent Nos. 5,985,356, 6,030,917 and WO 98/03521, all of which are incorporated herein by reference, generally disclose combinatorial methods.
  • the ligands, metal-ligand complexes or compositions may be prepared and/or tested in rapid serial and/or parallel fashion, e.g., in an array format.
  • ligands, metal-ligand complexes or compositions may take the form of an array comprising a plurality of compounds wherein each compound can be characterized by any of the above general formulas ⁇ i.e., I, II, III, etc.).
  • An array of ligands may be synthesized using the procedures outlined previously.
  • the array may also be of metal precursor compounds, the metal-ligand complexes or compositions characterized by the previously described formulae and/or description.
  • each member of the array will have differences so that, for example, a ligand or activator or metal precursor or R group in a first region of the array may be different than the ligand or activator or metal precursor or R group in a second region of the array. Other variables may also differ from region to region in the array.
  • each of the plurality of compositions or complexes has a different composition or stoichiometry, and typically each composition or complex is at a selected region on a substrate such that each compound is isolated from the other compositions or complexes.
  • This isolation can take many forms, typically depending on the substrate used. If a flat substrate is used, there may simply be sufficient space between regions so that there cannot be interdiffusion between compositions or complexes.
  • the substrate can be a microtiter or similar plate having wells so that each composition or complex is in a region separated from other compounds in other regions by a physical barrier.
  • the array may also comprise a parallel reactor or testing chamber.
  • the array typically comprises at least 8 compounds, complexes or compositions each having a different chemical formula, meaning that there must be at least one different atom or bond differentiating the members in the array or different ratios of the components referred to herein (with components referring to ligands, metal precursors, activators, group 13 reagents, solvents, monomers, supports, etc.).
  • Building Block Table C27, D1-D3, E2-E24, F1-F12, and G1-G4, are listed in the Building Block Table.
  • Building block BBl was purchased from Lancaster.
  • Building blocks BB5 and BB7 were purchased from Aldrich. All other building blocks listed in Building Block Table were prepared by Syngene.
  • Aryloximes and arylhyroximidoyl chlorides used for the synthesis of ligands A1-A35 were either available commercially or prepared using techniques known to those of skill in the art (see Liu, et al, J. Org. Chem. 1980, 45, 3916-3918). All boronic acids used were commercially available with the exception of 9- anthracenylboronic acid that was prepared as described in Scheme Dl.
  • 2,4- Dibromothiazole was purchased from Frontier Scientific. All benzils used for the synthesis of ligands E2-E16 were available commercially. Phenol protecting groups, methoxymethyl ether and methyl ether, were introduced using standard procedures known to those of skill in the art.
  • a reaction flask was charged, under N 2 , with BBlO (46 mg, 0.20 mmol), benzaldehyde oxime (0.066 rnL, 0.60 mmol), cyclohexane (4.0 mL), 2,6-lutidine (0.07 mL, 0.60 mmol), and N-chlorosuccinimide (80 mg, 0.60 mmol).
  • the reaction was heated at 8O°C for 18h.
  • Ligand A22 was synthesized using a slightly modified procedure to that described above for ligand Al. A mixture of the oxime (0.90 mmol), cyclohexane (3.0 mL), and iV-chlorosuccinimide (0.90 mmol) was first heated to 8O°C for Ih. After cooling to rt, a solution of BBIl (0.30 mmol) and 2,6-lutidine (0.90 mmol) in cyclohexane (3.0 mL) was added. The reaction was heated back to 8O°C for 18h. Ligand A22 was isolated in 58% yield.
  • Ligand A35 was synthesized as described for ligand Al except an aqueous workup was done prior to chromatography. Cyclohexane was removed by rotary evaporation and the crude reaction mixture was taken up in Et 2 O. The Et 2 O solution was washed twice with H 2 O, once with brine, and then dried over Na 2 SO 4 . Ligand A35 was isolated in 79% yield.
  • Ligands A3-A9 were synthesized as described above for ligand A2 in yields ranging from 49-84%.
  • Ligands A20, and A30-A32 were synthesized as described above for ligand A13. Ligand A20 was isolated in 91% yield, ligand A30 in 87% yield, ligand
  • Ligands AlO and All were synthesized as described for ligand A13 except the reaction temperature was 6O°C instead of 8O°C. Ligand AlO was isolated in
  • Ligands A33 and A34 were synthesized as described for ligand A13 except an aqueous workup was done prior to chromatography. Cyclohexane was removed by rotary evaporation and the crude reaction mixture was taken up in CH 2 Cl 2 .
  • Ligand A33 was isolated in 44% yield and ligand A34 in 62%yield.
  • Ligands B2 and B3 were synthesized as described above for ligand Bl in yields of 46% and 52%, respectively.
  • Ligands B4-B6 were synthesized as described for Bl except 5.0 eq of nitrile was used instead of 10.0 eq. Ligand B4 was isolated in 32% yield, ligand B5 in 42% yield, and ligand B6 in 57% yield.
  • n-BuLi (4.1 mL, 6.60 mmol, 1.6M in cyclohexane) was added dropwise to a solution of MOM-protected BB2 (1.92g, 5.5 mmol) in THF (20 mL) at -78°C under N 2 . After 30 min. at -78°C, triisopropylborate (1.65 mL, 7.15 mmol) was added and the reaction was warmed to rt. After Ih at rt, the reaction was quenched with MeOH (2 mL) then concentrated by rotary evaporation.
  • Ligands C25 and C27 were synthesized as described above for C24 in yields of 79% and 59%, respectively.
  • n-BuLi (2.4 niL, 3.84 mmol, 1.6M in cyclohexane) was added dropwise to a solution of methyl-protected BBl (1.Og, 3.34 mmol) in Et 2 O (10 mL) at -78°C under N 2 . After 30 min. at -78°C, triisopropylborate (0.88 mL, 3.84 mmol) was added and the reaction was warmed to rt. After Ih at rt, the reaction was quenched with MeOH (2 mL) then concentrated by rotary evaporation.
  • reaction flask was then charged, under N 2 , with 2,4-dibromothiazole (486 mg, 2.0 mmol), Pd(PPh 3 ) 4 (116 mg, 5 mol%), Na 2 CO 3 (1.1 mL, 2.0M solution in H 2 O), and toluene (10 mL).
  • the reaction was heated overnight at 9O°C. After cooling to rt, H 2 O was added and the layers were separated. The aqueous phase was extracted several times with CH 2 Cl 2 . The combined organic layers were washed with H 2 O, brine, and then dried over Na 2 SO 4 .
  • the crude reaction mixture was dissolved in CH 2 Cl 2 (5.0 mL) and BBr 3 (3.0 mL, 1.0M in CH 2 Cl 2 ) was added dropwise at rt. After Ih, the reaction was quenched with several drops of MeOH, washed with H 2 O, sat. NH 4 Cl (aq.), brine, and then dried over Na 2 SO 4 .
  • the crude product was purified by silica gel chromatography eluting with 1-2% Et 2 O in hexanes. Isolated 715 mg, 97% yield, of ligand C26 as a white solid.
  • Ligand C15 was synthesized, in 81% yield, as described for C2 except toluene was used as solvent and the reaction was run at 9O°C.
  • Ligand C16 was synthesized as described for C2 except the phenol was protected as the methyl ether instead of the methoxy methyl ether. Ligand C16 was obtained after deprotection with BBr 3 as described for C26. Ligand C16 was isolated in 32% yield.
  • n-BuLi (0.44 mL, 0.7 mmol, 1.6 M solution in cyclohexane) was added dropwise to a solution of MOM-protected BB2 (210 mg, 0.6 mmol) in Et 2 O (2.0 mL) at - 2O°C under N 2 .
  • triisopropylborate (0.17 mL, 0.72 mmol) was added and the reaction was warmed to rt and stirred for Ih. The reaction was quenched with MeOH (1.0 mL) then concentrated by rotary evaporation.
  • Ligands D2 and D3 were synthesized as described above in yields of 52% and 11%, respectively.
  • Ligands E2-E9 and E11-E16 were prepared as described above for ligand
  • Ligands El 7 and E19-E24 were synthesized as described above for ligand E18 in yields ranging from 61-91% with the exception of ligand E21 which was isolated in 31% yield.
  • Ligand Fl was synthesized as described above for ligand F7 with the exception that K 2 CO 3 was used instead Of Cs 2 CO 3 . Ligand Fl was isolated in 65% yield.
  • Fl was prepared by reacting BB7 with iV-methyl-l,2-phenylenediamine using techniques known to those of skill in the art.
  • Ligand F12 was synthesized in 62% yield as described above for ligand
  • Ligands Gl and G3 were synthesized as described above in isolated yields of 9% and 14%, respectively.
  • AU air sensitive procedures were performed under a purified argon or nitrogen atmosphere in a Vacuum Atmospheres or MBraun glove box.
  • AU solvents used were anhydrous, de-oxygenated and purified according to known techniques. All ligands and metal precursors were prepared according to procedures known to those of skill in the art, e.g., under inert atmosphere conditions, etc.
  • Group 13 reageants were purchased from Strem Chemicals Inc.
  • Activators were purchased from Boulder Scientific Company (Mead, CO) or prepared according to procedures known to those of skill in the art.
  • the vials contain parylene coated stir-bars and were weighed prior to their use in screening (described below). Solutions of a parent array of desired ligands were transferred to arrays of glass vials (0.3 - 0.6 ⁇ mol of each ligand) and the solvent was then removed from the ligand array using a nitrogen or argon stream. The resultant ligand array was contacted with a suitable group IV precursor, a group 13 reagent, 100 ⁇ l of 1-octene and an activator (or combination of group 13 reagents and activators, from a stock solution). A Teflon sheet and rubber gasket were then placed over the top of the array and an aluminum cover was screwed on the top to seal the array (reactor A). Specific details are described below. The aluminum block reactor (reactor A) has been described in U.S. Patent No. 6,507,645, which is incorporated by reference herein.
  • Solutions of metal precursors were prepared in toluene typically at 10 - 20 mmol/1: Ti(CH 2 C 6 H 5 ) 4 ; Zr(CH 2 C 6 H 5 ) 4 ; Hf(CH 2 C 6 H 5 ) 4 ; Ti(N(CH 3 ) 2 ) 4 ; Zr(N(CH 3 ) 2 ) 4 ; Hf(N(CH 3 ) 2 ) 4 ; TiC1 2 (N(CH 3 ) 2 ) 2 . [00345] Solutions of group 13 reagents were prepared in toluene typically at 50 -
  • Alumoxanes were supplied by Azko Chemical Inc., Chicago, IL.
  • Method 1 75°C Complexation, Reactor A, 75°C Screening: the ligand array (0.3 - 0.6 ⁇ mol of each ligand) was first contacted with toluene (ca. 100 ⁇ L per well) and then toluene solutions of the desired group IV precursor (15-30 ⁇ L per well, 0.3 ⁇ mol) were added. The resultant mixtures were stirred for a period of 30-45 minutes at 75 °C. The array was then treated with a stock solution- of the appropriate group 13 reagent activator (30 ⁇ L per well, contact time of ca. 10 min), followed by 100 ⁇ l of 1- octene, and finally an activator (or activator mixture, 30 - 75 ⁇ L per well). Immediately a Teflon sheet and rubber gasket were then placed over the top of the array and an aluminum cover was screwed on the top to seal the array (reactor A) and the array was stirred at 75°C for 1 hour.
  • toluene ca. 100 ⁇ L per well
  • Section 2Ci Ethylene-Styrene Copolymerization Examples in a 96-well
  • Ethylene-styrene copolymerization reactions were performed in a 96-well format using 8 mm x 30 mm tarred glass vials arranged in an 8 x 12 array within an aluminum block.
  • Reagents were added from stock solutions or slurries to the 8 mm x 30 mm vials using a Cavro liquid handling robot driven by library design and/or automation software, such as Library Studio® and Impressionist® software, available from Symyx Technologies, Inc., of Santa Clara, California, which is described in European Patent No. 1080435, U.S. Patent No. 6,507,645, and European Patent No. 1175645.
  • the vials contain parylene coated stir-bars and were weighed prior to their use in screening (described below). Solutions of a parent array of desired ligands were transferred to arrays of glass vials (0.3 - 0.6 ⁇ mol of each ligand) and the solvent was then removed from the ligand array using a nitrogen or argon stream. The resultant ligand array was contacted with a suitable group IV precursor, a group 13 reagent and an activator (or combination of group 13 reagents and activators, from a stock solution), followed by 20 ⁇ l of styrene. The array was sealed with a reactor top capable of delivering gaseous reagent(s) (reactor B) and pressurized with ethylene. Specific details are described below. The HiP reactor (reactor B) is described in U.S. Patent Publication No. 2003- 0161763, which is incorporated herein by reference.
  • Solutions of metal precursors were prepared in toluene typically at 10 - 20 mmol/1: Ti(CH 2 C 6 H 5 ) 4 ; Zr(CH 2 C 6 H 5 ) 4 ; Hf(CH 2 C 6 H 5 ) 4 ; Ti(N(CH 3 ) 2 ) 4 ; Zr(N(CH 3 ) 2 ) 4 ;
  • Alumoxanes were supplied by Azko Chemical Inc., Chicago, IL.
  • Method 1 75°C Complexation, Reactor B, 75°C Screening: the ligand array (0.3 - 0.6 ⁇ mol of each ligand) was first contacted with toluene ⁇ pa. 100 ⁇ L per well) and then toluene solutions of the desired group IV precursor (30 ⁇ L per well, 0.3 ⁇ mol) were added. The resultant mixtures were stirred for a period of 30-45 minutes at 75°C. The array was then treated with a stock solution of the appropriate group 13 reagent activator (30 ⁇ L per well, contact time of ca. 10 min), followed by an activator (or activator mixture, 30 - 75 ⁇ L per well, contact time of ⁇ 5 min).
  • the array of vials was then transferred to a fume hood, and to each vial was quenched by 500 ⁇ L of acidified methanol.
  • a Teflon sheet and rubber gasket are then placed over the top of the array and an aluminum cover was screwed on the top to seal the array.
  • the array was . first mechanically agitated for approximately an hour and then centrifuged at 1500 rpm for 10 minutes.
  • the acidified methanol solution was decanted off. This process was repeated twice more with acidified methanol, followed by three washing rounds using methylethylketone (MEK) to remove soluble polystyrene.
  • MEK methylethylketone
  • TCB 1,2,4-Trichlorobenzene
  • Solutions of metal precursors were prepared in toluene typically at 10 mmol/1: Ti(CH 2 C 6 H 5 ) 4 ; Zr(CH 2 C 6 H 5 ) 4 ; Hf(CH 2 C 6 H 5 ) 4 ; Ti(N(CH 3 ) 2 ) 4 ; Zr(N(CH 3 ) 2 ) 4 ; Hf(N(CH 3 ) 2 ) 4 ; TiCl 2 (N(CH 3 ) 2 ) 2 .
  • Method 1 75°C Complexation, Reactor B, 75°C Screening: the ligand array (0.3 - 0.6 ⁇ mol of each ligand) was first contacted with toluene (ca. 100 ⁇ L per well) and then toluene solutions of the desired group IV precursor (30 ⁇ L per well, 0.3 ⁇ mol) were added. The resultant mixtures were stirred for a period of 30-45 minutes at 75°C. The array was then treated with a stock solution of the appropriate group 13 reagent activator (30 ⁇ L per well, contact time of ca. 10 min), followed by an activator (or activator mixture, 30 - 75 ⁇ L per well, contact time of ⁇ 5 min). The array was sealed using a reactor top capable of delivering gaseous reagent(s) (reactor B) and stirred at 75°C under 80 psi of propylene for 1 hour.
  • toluene ca. 100 ⁇ L per well
  • toluene solutions of the desired group IV precursor (30 ⁇
  • Method 2 75°C Complexation, Reactor C, 75°C Screening: the ligand array (0.3 - 0.6 ⁇ mol of each ligand) was first contacted with toluene (ca. 100 ⁇ L per well) and then toluene solutions of the desired group IV precursor (30 ⁇ L per well, 0.3 ⁇ mol) were added. The resultant mixtures were stirred for a period of 30-45 minutes at 75°C. The array was then treated with a stock solution of the appropriate group 13 reagent activator (30 ⁇ L per well, contact time of ca.
  • the array of vials was then transferred to a fume hood, and to each vial was quenched by added 100 - 300 uL of methanol. The volatiles were removed by using a nitrogen stream, followed by drying the array over-night in vacuo. The vials were weighed in order to determine the yield of polymer produced. 1,2,4-Trichlorobenzene (TCB) was added vials which met a minimum yield criteria, and the resulting TCB solutions were heated for 2 hours at 140°C. An aliquot of the hot solution was deposited on a wafer, in order to form a thin film. The resultant polymer thin-films were analyzed via a rapid-FT-IR method (details in the secondary screening section) to determine tacticity. Table 2C presents the results from the propylene homopolymerization reactions performed in a 96-well format.
  • the system was operated at an eluent flow rate of 1.5 mL/min and an oven temperature of 160°C; o- dichlorobenzene was used as the eluent; the polymer samples were dissolved 1,2,4- trichlorobenzene at a concentration of about 5 mg/mL; 200 ⁇ L of a polymer solution were injected into the system; and the concentration of the polymer in the eluent was monitored using an evaporative light scattering detector. All of the molecular weight results obtained are relative to linear polystyrene standards.
  • DSC Differential Scanning Calorimetry
  • Section 3A Propylene Polymerizations using metal-ligand compositions: A total of 23 separate polymerization reactions were performed as follows.
  • Method A A pre-weighed glass vial insert and disposable stirring paddle were fitted to each reaction vessel of the reactor. The reactor was then closed, 0.200 mL of a 0.05 M solution of Modified Methylaluminoxane 3A (from Azko Chemical Inc., Chicago, II) ("MMAO") in toluene and 3.8 mL of toluene were injected into each pressure reaction vessel through a valve. The temperature was then set to the appropriate setting (with specific temperatures for each polymerization being listed in Table 3A and Table 3B, below), and the stirring speed was set to 800 rpm unless otherwise noted. The mixture was exposed to propylene at 100 psi pressure. A propylene pressure of 100 psi in the pressure cell and the temperature setting were maintained, using computer control, until the end of the polymerization experiment.
  • MMAO Modified Methylaluminoxane 3A
  • Section 3 AU In situ preparation of metal-ligand compositions
  • Method ZA 24 ⁇ L of the ligand solution (25 mM in 1,2-dichloroethane) was dispensed in a 1 mL glass vial followed by the removal of solvent. To the 1 mL glass vial containing the ligand was added toluene (50 ⁇ L) followed by the addition of an equimolar amount of metal precursor solution (10 mM in toluene) to form the metal-ligand composition solution. The reaction mixture was heated at 75 °C for 35 min.
  • Method ZB Similar to Method ZA except that 60 ⁇ l of the ligand solution (10 mM in 1,2-dichloroethane) was dispensed in the 1 mL glass vial.
  • Method ZC 48 ⁇ l of the ligand solution (25 mM in 1,2-dichloroethane) was dispensed in a 1 mL glass vial followed by the removal of solvent. To the 1 mL glass vial containing the ligand was added toluene (50 ⁇ L) followed by the addition of 0.5 mol equivalents of metal precursor solution (10 mM in toluene) to form the metal-ligand composition solution. The reaction mixture was heated at 75 °C for 35 min.
  • Method ZD Similar to Method ZC except that 120 ⁇ L of the ligand solution (10 mM in 1,2- dichloroethane) was dispensed in the ImL glass vial.
  • Method ZE Similar to Method ZC except that 60 ⁇ L of toluene (instead of 50 ⁇ L) was added to the ImL glass vial containing the ligand prior to the addition of the metal precursor and the reaction mixture was kept at ambient temperature prior to screening.
  • Method ZF 40 ⁇ L of the ligand solution (25 mM in toluene) was dispensed in a ImL glass vial followed by the removal of solvent.
  • Method ZH 48 ⁇ L of the ligand solution (25 mM in toluene) was dispensed in a ImL glass vial followed by the removal of solvent. To the ImL glass vial containing the ligand was added toluene (60 ⁇ L) followed by the addition of 0.5 mol equivalents of the metal precursor solution (10 mM in toluene) to form the metal-ligand composition solution. The reaction mixture was heated at 75 °C for 45 min.
  • Method ZI Similar to Method ZH except that 40 ⁇ L (instead of 50 ⁇ L) of toluene was added to the 1 mL glass vial prior to the addition of the metal precursor and the reaction mixture was kept at ambient temperature prior to screening.
  • Method ZJ 24 ⁇ L of the ligand solution (25 mM in 1,2-dicliloroethane) was dispensed in a 1 mL glass vial followed by the removal of solvent. To the ImL glass vial containing the ligand was added toluene (40 ⁇ L) followed by the addition of an equimolar amount of metal precursor solution (10 mM in toluene) to form the metal- ligand composition solution. The reaction mixture was heated at 75 °C for 45 min.
  • Method ZK Similar to Method ZJ except that 24 ⁇ L of the ligand solution (25 mM in toluene) was dispensed in the 1 mL glass vial.
  • Method ZL Similar to ZH except that 96 ⁇ L of the ligand solution (25 mM in toluene) was dispensed in the 1 mL glass vial.
  • Method ZM Similar to Method ZJ except that 48 ⁇ L of the ligand solution (25 mM in toluene) was dispensed in the ImL glass vial.
  • Method ZN 40 ⁇ L of the ligand solution (25 mM in toluene) was dispensed in a 1 mL glass vial followed by the removal of solvent.
  • Method ZO Similar to method ZN except that 100 ⁇ L of the ligand solution ( 10 mM in toluene) was dispensed into the ImL glass vial.
  • Method ZP Similar to Method ZN except that 60 ⁇ L (instead of 100 ⁇ L) of toluene was added to the 1 mL glass vial prior to the addition of metal precursor.
  • Method ZQ 20 ⁇ L of the ligand solution (25 mM in toluene) was dispensed in a 1 mL glass vial followed by the removal of solvent. To the 1 mL glass vial containing the ligand was added toluene (40 ⁇ L ) followed by the addition of an equimolar amount of the metal precursor (5 mM in toluene) to form the metal-ligand composition solution. The reaction mixture was heated at 70 °C for 1 h.
  • Method ZR Similar to Method ZQ except that a 25 mM ligand solution in 1,2-dichloroethane was used.
  • Section 3Aiii Preparation of the group 13 reagent and activator stock solutions.
  • the "activator solution” is a solution of N,N'-dimethylanilinium tetrakis
  • ABS 20 penentafluorophenyl borate
  • ABS 20 N,N'-dimethylanilinium tetrakis
  • BF 15 tris(pentafluorophenyl)borane
  • ABSC tris(pentafluorophenyl)borane
  • the “group 13 reagent” solution is either a solution of trimethylaluminum (“TMA”), triisobutylaluminium (“TIBA”) or a solution of nonhydrolytic polymethylaluminoxane (Akzo Nobel PMAO-IP, referred to below as "PMAO", available from Akzo Nobel Polymer Chemicals, Chicago, Illinois, USA), all “group 13 reagent” solutions were in toluene.
  • TMA trimethylaluminum
  • TIBA triisobutylaluminium
  • PMAO nonhydrolytic polymethylaluminoxane
  • Method AAAA To the 1 mL glass vial containing the metal-ligand composition, the appropriate amount of the group 13 reagent solution as a 50 mM solution, containing the indicated equivalents of group 13 reagent (per metal precursor) in the specific example, was added. After about 11 minutes, 1.1 mol equivalents (per metal precursor) of the activator solution (2.5 mM) was added to the 15 mL vial and the reaction mixture was mixed.
  • Method BBBB To the 1 mL glass vial containing the metal-ligand composition, the appropriate amount of the group 13 reagent solution as a 50 niM solution, containing the indicated equivalents group 13 reagent (per metal precursor) in the specific example, was added.
  • Method CCCC Similar to Method AAAA except that the activator solution was a toluene solution of the mixture of ABF 20 and BF 15 (2.5mM ABF 20 /5mM BF 15 ) and a total of 3.3 mol equivalents (per metal precursor) was used.
  • Method DDDD Similar to method AAAA except that 200 mM of group 13 reagent solution and 5 mM activator solution were used (instead of 50 mM and 2.5 mM respectively) and the total volume injected was 1.0 mL (instead of 0.8 mL).
  • Method EEEE Similar to Method DDDD except that a total of 3.3 mol equivalents (per metal precursor) of the activator (5 mM ABF 20 /10 mM BF 15 ) was used.
  • Method FFFF Similar to method BBBB except that a total of 3.3 mol equivalents (per metal precursor) of the activator (2.5 mM ABF 20 /5.0 mM BF 15 ) was used and 400 ⁇ L of toluene was added to the 1 mL vial immediately after the activator.
  • Method GGGG Similar to method AAAA except that a total of 3.3 mol equivalents (per metal precursor) of the activator solution (2.5mM ABF 20 /5.0mM BF 15 ) was used and the total volume injected to the reaction vessel was 0.5 mL (instead of 0.8 mL).
  • Method HHHH To the 1 mL glass vial containing the metal-ligand composition, the appropriate amount of the group 13 reagent solution as a 50 mM solution, containing the indicated equivalents group 13 reagent (per metal precursor) in the specific example, was added.
  • Method JJJJ Similar to Method HHHH except that 200 mM of group 13 reagent solution and 5mM ABF 20 /10mM BF 15 were used and the total volume injected to the pre-pressurized reaction vessel was 0.8 niL.
  • Method KKKK To the 1 niL glass vial containing the metal-ligand composition, the appropriate amount of the group 13 reagent solution as a 50 mM solution, containing the indicated equivalents of group 13 reagent (per metal precursor) in the specific example, was added followed by an immediate addition of 300 ⁇ L of toluene.
  • Method MMMM Similar to Method AAAA except that the total volume injected to the pre-pressurized reaction vessel was 0.5 mL.
  • Method NNNN Similar to method AAAA except that the total volume injected was 1.0 mL (instead of 0.8 mL).
  • the polymerization reaction was allowed to continue for 60-1800 seconds, during which time the temperature and pressure were maintained at their pre-set levels by computer control.
  • the specific polymerization times for each polymerization are shown in Table 3A.
  • the reaction was quenched by addition of an overpressure of carbon dioxide sent to the reactor.
  • the polymerization times were the lesser of the maximum desired polymerization time or the time taken for a predetermined amount of monomer gas to be consumed in the polymerization reaction.
  • the glass vial insert containing the polymer product and solvent, was removed from the pressure cell and removed from the inert atmosphere dry box.
  • the volatile components were removed using a centrifuge vacuum evaporator. After most of the volatile components had evaporated, the vial contents were dried thoroughly by evaporation at elevated temperature under reduced pressure. The vial was then weighed to determine the yield of polymer product.
  • the polymer product was then analyzed by rapid GPC, as described above, to determine the molecular weight of the polymer produced, and by FTIR spectroscopy to determine the crystallinity index. The melting point of selected samples was measured by DSC, as described above.
  • the polymerization reactor was prepared in the manner described in
  • Section 3BH Preparation of the group 13 reagent and activator stock solutions
  • the "activator solution” is either a solution of N,N'-dimethylanilinium tetrakis (pentafluorophenyl) borate ("ABF 2 o") in toluene or .a solution of trityl tetrakis (pentafluorophenyl) borate ("TBF 20 ”) in toluene.
  • the "ABF 20 " solution is heated to approximately 85°C to dissolve the reagent.
  • the "TBF 20 " solution is at ambient temperature.
  • the molarity is indicated in the "activation method" of the individual example described below.
  • the "group 13 reagent solution” is either a solution of trimethylaluminium ("TMA”) or a solution of tri-isobutyl aluminium (“TIBA”).
  • TMA trimethylaluminium
  • TIBA tri-isobutyl aluminium
  • Section 3Biii Activation method and injection of solutions into the pressure reactor vessel
  • Method AA 40 ⁇ L of a 5OmM solution of the group 13 reagent was dispensed into a 1 mL vial. 80 ⁇ L of complex solution (5 mM in toluene) containing 0.4 ⁇ mol metal complex was added. After about 12 min, 176 ⁇ L of the activator solution in toluene (2.5 niM) was added to the 1 niL vial and the contents of the 1 mL vial were mixed.
  • the polymerization reaction was allowed to continue for 60-1800 seconds, during which time the temperature and pressure were maintained at their pre-set levels by computer control.
  • the specific polymerization times for each polymerization are shown in Table 3B.
  • the reaction was quenched by addition of an overpressure of carbon dioxide sent to the reactor.
  • the polymerization times were the lesser of the maximum desired polymerization time or the time taken for a predetermined amount of monomer gas to be consumed in the polymerization reaction.
  • the glass vial insert containing the polymer product and solvent, was removed from the pressure cell and removed from the inert atmosphere dry box.
  • the volatile components were removed using a centrifuge vacuum evaporator. After most of the volatile components had evaporated, the vial contents were dried thoroughly by evaporation at elevated temperature under reduced pressure. The vial was then weighed to determine the yield of polymer product.
  • the polymer product was then analyzed by rapid GPC, as described above, to determine the molecular weight of the polymer produced, and by FTIR spectroscopy to determine the crystallinity index.
  • Method B A pre- weighed glass vial insert and disposable stirring paddle were fitted to each reaction vessel of the reactor. The reactor was then closed, 0.200 niL of a 0.05 M solution of Modified Methylaluminoxane 3A (from Azko Chemical Inc., Chicago, II) ("MMAO") in toluene, 0.400 mL of octene and 4.4 niL of toluene were injected into each pressure reaction vessel through a valve. The temperature was then set to the appropriate setting (with specific temperatures for each polymerization being listed in Table 3 C and Table 3D, below), and the stirring speed was set to 800 rpm unless otherwise noted. The mixture was exposed to ethylene at 100 psi pressure. An ethylene pressure of 100 psi in the pressure cell and the temperature setting were maintained, using computer control, until the end of the polymerization experiment. [00404] Method C: Method C is similar to method B except that 0.200 mL of a
  • Section 3Ciii Activation methods and injection of solutions into the pressure reactor vessel
  • the glass vial insert containing the polymer product and solvent, was removed from the pressure cell and removed from the inert atmosphere dry box.
  • the volatile components were removed using a centrifuge vacuum evaporator. After substantial evaporation of the volatile components, the vial contents were dried thoroughly by evaporation at elevated temperature under reduced pressure. The vial was then weighed to determine the yield of polymer product.
  • the polymer product was then analyzed by rapid GPC, as described above to determine the molecular weight of the polymer produced, and FTIR spectroscopy to determine the comonomer incorporation. Results are presented in Table 3C.
  • the reactor was prepared as described in Methods B and C, above. In some examples hydrogen (as a mixture with nitrogen) was added; the amount added is noted in Table 3D. An ethylene pressure of 100 psi in the pressure cell and the temperature setting were maintained, using computer control, until the end of the polymerization experiment.
  • the "activator solution” is either a 2.5 mM solution of N,N'- dimethylanilinium tetrakis (pentafluorophenyl) borate (“ABF 20 ”) in toluene or a 400 mM solution of Modified Methylaluminoxane - 3A (Azko) ("MMAO") in toluene.
  • the "ABF 20 " solution is heated to approximately 85°C to dissolve the reagent.
  • the "MMAO” solution is at ambient temperature.
  • the group 13 reagent solution is either a solution of triisobutylaluminium or modified methalumoxane-3 A (“MMAO”) in toluene.
  • the molarity of the group 13 reagent is noted below and the molar equivalents is noted in Table 3D.
  • Method AAA 75 ⁇ L of a 20 mM solution of the group 13 reagent was dispensed into a 1 niL vial. 60 ⁇ L of complex solution (5 mM in toluene) containing 0.3 ⁇ mol metal complex was added. After about 45 seconds, 132 ⁇ L of the activator solution in toluene (2.5 mM) was added to the 1 mL vial followed by an immediate addition of 700 ⁇ L of toluene and the contents of the 1 mL vial were mixed.
  • Method BBB Similar to Method AAA, except that 340 ⁇ L of toluene (instead of 700 ⁇ L) was added to the 1 mL vial immediately after the activator.
  • Method CCC Similar to Method BBB, except that 150 ⁇ L of a 400 mM activator solution was used.
  • Method DDD Similar to Method CCC, except that 150 ⁇ L of a 400 mM group 13 reagent solution was added to the ImL vial prior to the addition of the metal complex and 700 ⁇ L (instead of 340 ⁇ L) of toluene was added to the 1 mL vial immediately after the activator.
  • Method EEE Similar to Method DDD except that 340 ⁇ L of toluene was added to the 1 mL vial immediately after the activator.
  • Method FFF Similar to Method AAA, except that 340 ⁇ L (instead of 700 ⁇ L) of toluene was added to the 1 mL vial immediately after the activator.
  • Method GGG Similar to Method CCC except that 700 ⁇ L (instead of 340 ⁇ L) of toluene was added immediately after the activator.
  • Method HHH 50 ⁇ L of a 20 mM solution of the group 13 reagent was dispensed into a 1 mL vial. 50 ⁇ L of complex solution (4 mM in toluene) containing 0.2 ⁇ mol metal complex was added. After about 12 min, 88 ⁇ L of the activator solution in toluene (2.5 mM) was added to the 1 mL vial immediately followed by the addition of 800 ⁇ L of toluene and the contents of the 1 mL vial were mixed.
  • Method MMM Similar to Method LLL except that 150 ⁇ L of toluene was added after complex.
  • Method NNN 40 ⁇ L of a 5OmM solution of the group 13 reagent was dispensed into a 1 mL vial. 80 ⁇ L of complex solution (5 mM in toluene) containing 0.4 ⁇ mol metal complex was added.
  • the polymerization reaction was allowed to continue for 60-600 seconds, during which time the temperature and pressure were maintained at their pre-set levels by computer control.
  • the specific times for each polymerization are shown in Table 3D.
  • the polymerization times were the lesser of the maximum desired polymerization time or the time taken for a predetermined amount of monomer gas to be consumed in the polymerization reaction.
  • the reaction was quenched by addition of an overpressure of carbon dioxide sent to the reactor.
  • the glass vial insert containing the polymer product and solvent, was removed from the pressure cell and removed from the inert atmosphere dry box.
  • the volatile components were removed using a centrifuge vacuum evaporator. After substantial evaporation of the volatile components, the vial contents were dried thoroughly by evaporation at elevated temperature under reduced pressure. The vial was then weighed to determine the yield of polymer product.
  • the polymer product was then analyzed by rapid GPC, as described above to determine the molecular weight of the polymer produced, and FTIR spectroscopy to determine the comonomer incorporation. Results are presented in Table 3D.
  • Section 3E Styrene polymerizations in 12-well format
  • Section 3Ei Stock Solutions: Solutions of metal precursors were prepared in toluene typically at 10 - 20 mmol/1: Ti(CH 2 C 6 H 5 ) 4 ; Zr(CH 2 C 6 H 5 ) 4 ; Hf(CH 2 C 6 H 5 ) 4 ; Ti(N(CH 3 ) 2 ) 4 ; Zr(N(CH 3 ) 2 ) 4 ; Hf(N(CH 3 ) 2 ) 4 ; TiCl 2 (N(CH 3 ) 2 ) 2 ; [Ti(CH 2 C 6 H 5 ) 3 + ][C 6 H 5 CH 2 B(C 6 Fs) 3 -]; [Zr(CH 2 C 6 H 5 ) 3 + ][C 6 HsCH 2 B(C 6 F 5 ) 3 -] and [Hf(CH 2 C 6 H 5 ) 3 + ][C 6 H 5 CH 2 B(C 6 Fs) 3 " ] were generated in situ within the 12 well arrays by
  • Solutions of group 13 reagents were prepared in toluene typically at 50 - 250 mmol/1: Al(Me) 3 , (TMA); Al(Et) 3 , (TEA); Al( i Bu) 3 ,(TIBA); PMAO-IP & MMAO-3A.
  • Alumoxanes were supplied by Azko Chemical Inc., Chicago, IL.
  • Section 3EH Reactor Set-up: Organized in 4 x 3 arrays within an aluminum block, pre-mix catalyst solutions were prepared 8*30 mm vials (containing parylene coated stir-bars) using a pipette or liquid handling robot driven by software (available from Symyx Technologies, Inc., Santa Clara and described within EP 1080435, US 6507645, and EP 1175645).
  • the pre-mix catalyst solutions contain toluene; one or two ligands (0.3 - 1.5 ⁇ mol); a specified group IV metal precursor; a group 13 reagent; and an activator (or combination of group 13 reagents and activators, from a stock solution).
  • Section 3Eiii Polymerization conditions: Seven different processing conditions were used for these polymerizations, with the conditions being presented in Table 3E by reference to the method number.
  • Method 1 In-situ Complexation: 1 ligand species per' well; 25°C complexation, 105°C reaction temperature; ca. 4 mL total volume per well: The ligand array (1.0 - 2.0 ⁇ mol of each ligand) was first contacted with toluene (ca. 100 ⁇ L per well) and then toluene solutions of the desired group IV precursor (15-60 ⁇ L per well, 0.5 - 1.0 ⁇ mol) were added.
  • the resultant mixtures were stirred for a period of 45 - 60 minutes at 25°C within an Al block (pre-mix array).
  • Individual vials were then treated with a stock solution of the appropriate group 13 reagent activator (30-60 ⁇ L per well, contact time of ca. 10 min, 25°C), followed by an activator (or activator mixture, 30 - 75 ⁇ L per well, contact time of ca. 2 min, 25°C).
  • Individual aliquots of the solutions contained within the pre-mix array were transferred to 15 mL tarred glass vials containing Teflon coated stir bars; 2.0 mL of styrene, 2.0 ml toluene and a group 13 scavenger (10 ⁇ mol).
  • the vials were housed within a reactor, with its heater pre-set at 105°C temperature; and it stirrer set at 300 - 800 rpm. 2 - 25 minutes post addition of the catalyst solutions, the vials were removed from the reactor; placed into a RT Al block; and 3 mL of cold toluene was injected into each well. The 15 mL vials were then removed from the glove box and transferred to a fume hood to be quenched with 5 mL of methanol.
  • Method 2 In-situ Complexation; 1 ligand species per well; 75°C complexation, 105°C reaction temperature; ca.
  • the ligand array (1.0 - 2.0 ⁇ mol of each ligand) was first contacted with toluene (ca. 100 ⁇ L per well) and then toluene solutions of the desired group IV precursor (15-60 ⁇ L per well, 0.5 - 1.0 ⁇ mol) were added. The resultant mixtures were stirred for a period of 45 minutes at 75°C within an Al block (pre-mix array). The pre-mix array was allowed to cool to RT ⁇ ca. 25°C). Individual vials were then treated with a stock solution of the appropriate group 13 reagent activator (30-60 ⁇ L per well, contact time of ca.
  • Method 4 In-situ Complexation: 1 ligand species per well; 25°C complexation. 125°C reaction temperature; ca. 4 mL total volume per well: Procedure equivalent to Method 1 except: 1) reactor temperature equals 125°C; 2) and 2.0 mL ethylbenzene instead of 2.0 mL toluene as solvent within 15 mL vial.
  • Method 5 In-situ Complexation; 1 ligand species per well; 75°C complexation, 125°C reaction temperature: ca.
  • the ligand array (0.75 ⁇ mol of each ligand 1 & 0.75 ⁇ mol of each ligand 2) was first contacted with toluene (ca. 100 ⁇ L per well) and then toluene solutions of the desired group IV precursor (50 ⁇ L per well, 0.75 ⁇ mol) were added. The resultant mixtures were stirred (at 25°C) within an Al block (pre-mix array). Individual vials were then treated with a stock solution of the appropriate group 13 reagent activator (30-60 ⁇ L per well, contact time of ca. 10 min, 25°C), followed by an activator (or activator mixture, 30 - 75 ⁇ L per well, contact time of ca. 2 min, 25°C).
  • Section3Eiv Product Analysis: Post methanol quench, the array was dried over-night in vacuo to remove the liquid phase, followed by 2 - 4 hour drying cycles within a vacuum oven set at 130°C. The vials were weighed via an automated weigh station, to constant weight. 1,2,4-Trichlorobenzene (TCB) was added vials which met a minimum yield criteria, and the resulting TCB solutions were heated for 2 hours at 160°C. An aliquot of the hot solution was injected into a rapid HT-GPC in order to determine Mw and PDI. Table 3E present representative results from the styrene homopolymerization reactions performed in a 12- well format.
  • Section 3F Slurry ethylene-1-octene copolymerizations
  • Section 3Fi Preparation of the slurry polymerization reactor: The slurry parallel pressure reactor is described in U.S. Patent 6,759,014, which is incorporated herein by reference. A pre-weighed glass vial insert and disposable stirring paddle were fitted to each reaction vessel of the reactor. The reactor was then closed, 0.200 niL of a 0.02 M solution of tri- «-octylaluminum (Sigma-Aldrich) ("TNOA”) in heptane, 0.125 niL of 1-octene and 4 niL of heptane were injected into, each pressure reaction vessel through a valve.
  • TNOA tri- «-octylaluminum
  • Section 3Fiii Injection of supported catalyst slurries into the slurry pressure reactor vessel Supported catalysts were vortexed at 1200 rpm throughout the experiment and during syringe aspiration prior to delivery of the catalyst to the reactor. A 90-100 uL buffer of heptane followed by 100-150 ⁇ L of the supported catalyst were injected into the pre-pressurized reaction vessel and were followed immediately by injection of heptane to increase the total volume injected to 0.600 mL.
  • Section 3Fiv Polymerization The polymerization reaction was allowed to continue for 300-600 seconds, during which time the temperature and pressure were maintained at their pre-set levels by computer control.
  • the specific times for each polymerization are shown in Table 3F.
  • the polymerization times were the lesser of the maximum desired polymerization time or the time taken for a predetermined amount of monomer gas to be consumed in the polymerization reaction. After the reaction time elapsed, the reaction was quenched by addition of an overpressure of carbon dioxide sent to the reactor.
  • Section 3Fv Product work up After the polymerization reaction, the glass vial insert, containing the polymer product and solvent, was removed from the pressure cell and removed from the inert atmosphere dry box, and the volatile components were removed using a centrifuge vacuum evaporator. After most of the volatile components had evaporated, the vial contents were dried thoroughly by evaporation at elevated temperature under reduced pressure. The vial was then weighed to determine the yield of polymer product. The polymer product was then analyzed by Rapid GPC, to determine the molecular weight of the polymer produced, and by FTIR spectroscopy to determine the mole percent octene incorporated in the polymer as described above.
  • a toluene solution OfZrBz 4 (104 mg, 0.23 mmol, 4 mL) was added dropwise to a toluene solution of phenol oxadiazole A13 (200 mg, 0.46 mmol, 12 mL). The mixture was stirred for Ih at room temperature. The volatiles were removed and the resulting residue was washed with pentane and dried under vacuum (190 mg, 73%).
  • a toluene solution OfHfBz 4 (24 mg, 0.044 mmol, 3mL) was added to a toluene solution of phenol oxadiazole A14 (41 mg, 0.088mmol, 3mL). The mixture was stirred for 35 min at room temperature and the titled complex formed quantitatively as determined by 1 H NMR. The volatiles were removed and a yellow solid product was obtained which was used for polymerization screening without further purification.
  • a toluene solution OfZrBz 4 (35 mg, 0.078 mmol, 2 mL) was added dropwise to a toluene solution of phenol oxadiazole A31 (82 mg, 0.155 mmol, 4 mL). The mixture was stirred for Ih at room temperature. The mixture was concentrated until almost to dryness and pentane (0.5 mL) was added. The mixture was stored at -35 C for 12 h and an orange solid product was obtained which was then washed with pentane and dried under vacuum. (78mg, 76 %).
  • a toluene solution OfZrBz 4 (103 mg, 0.23 mmol, 6 mL) was added dropwise to a toluene solution of phenol thiazole C14 (206 mg, 0.45 mmol, 8 mL). The mixture was stirred for Ih at room temperature. The volatiles were removed to almost dryness and pentane was added. The mixture was kept at -35 °C for Ih, an orange solid product was collected and dried (265 mg, 99 %).
  • a toluene solution OfZrBz 4 (25 mg, 0.054 mmol, 1 mL) was added dropwise to a toluene solution of phenol thiazole C23 (44 mg, 0.11 mmol, 1.4 mL). The mixture was stirred for Ih at room temperature. The volatiles were removed and the residue was washed with pentane and dried, light orange solid product was collected (49 mg, 83 %).
PCT/US2005/045766 2004-12-16 2005-12-16 Phenol-heterocyclic ligands, metal complexes, and their uses as catalysts WO2006066126A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63655504P 2004-12-16 2004-12-16
US60/636,555 2004-12-16

Publications (2)

Publication Number Publication Date
WO2006066126A2 true WO2006066126A2 (en) 2006-06-22
WO2006066126A3 WO2006066126A3 (en) 2006-08-24

Family

ID=36282632

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/045766 WO2006066126A2 (en) 2004-12-16 2005-12-16 Phenol-heterocyclic ligands, metal complexes, and their uses as catalysts

Country Status (2)

Country Link
US (2) US7705157B2 (US07705157-20100427-C00078.png)
WO (1) WO2006066126A2 (US07705157-20100427-C00078.png)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076589A1 (en) 2006-12-20 2008-06-26 Exxonmobil Chemical Patents Inc. Phase separator and monomer recycle for supercritical polymerization process
US7834039B2 (en) 2006-12-15 2010-11-16 Abbott Laboratories Oxadiazole compounds
WO2010132811A1 (en) * 2009-05-14 2010-11-18 Univation Technologies, Llc Mixed metal catalyst systems having a tailored hydrogen response
JP2021522243A (ja) * 2018-04-26 2021-08-30 エクソンモービル ケミカル パテンツ インコーポレイテッド 長鎖アルキル基を有するカチオンを含有する非配位性アニオン型活性化剤
WO2021242800A1 (en) 2020-05-29 2021-12-02 Dow Global Technologies Llc Attenuated post-metallocene catalysts
WO2021242801A1 (en) 2020-05-29 2021-12-02 Dow Global Technologies Llc Attenuated hybrid catalysts

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100249161A1 (en) * 2006-11-15 2010-09-30 Anders Klarskov Petersen 2- ( 2 -hydroxyphenyl) -quinazolin-4-ones useful for treating obesity and diabetes
US8022066B2 (en) * 2006-11-15 2011-09-20 High Point Pharmaceuticals, Llc 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
WO2008059023A1 (en) * 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc New haloalkylsulfone substituted compounds useful for treating obesity and diabetes
WO2008059026A1 (en) * 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
US8431660B2 (en) * 2007-12-05 2013-04-30 Lg Chem, Ltd. Non-metallocene catalysts having tetrazol group for olefin polymerization and polymerizing method of olefin using the same
US20090286944A1 (en) * 2008-05-15 2009-11-19 Symyx Technologies, Inc. Select phenol-heterocycle ligands, metal complexes formed therefrom, and their uses as catalysts
CA2786286C (en) 2008-12-31 2017-03-14 Symyx Solutions, Inc. Method for producing very-high or ultra-high molecular weight polyethylene
JP5709389B2 (ja) 2009-03-20 2015-04-30 株式会社半導体エネルギー研究所 オキサジアゾール誘導体、発光素子、発光装置及び電子機器
JP5539687B2 (ja) * 2009-09-10 2014-07-02 東レ・ダウコーニング株式会社 アルキル変性ポリジメチルシロキサン精製品の製造方法、該精製品を含有する化粧料原料および化粧料
US8541522B2 (en) * 2009-10-28 2013-09-24 Exxonmobil Chemical Patents Inc. Catalyst compounds and use thereof
CN102597015A (zh) * 2009-10-28 2012-07-18 埃克森美孚化学专利公司 催化剂化合物和它们的用途
WO2011056432A2 (en) 2009-10-28 2011-05-12 Exxonmobil Chemical Patents Inc. Catalyst compounds and use thereof
WO2011056431A2 (en) * 2009-10-28 2011-05-12 Exxonmobil Chemical Patents Inc. Catalyst compounds and use thereof
US8557936B2 (en) * 2009-10-28 2013-10-15 Exxonmobil Chemical Patents Inc. Catalyst compounds and use thereof
US9228061B2 (en) 2011-09-07 2016-01-05 Dow Corning Corporation Zirconium containing complex and condensation reaction catalysts, methods for preparing the catalysts, and compositions containing the catalysts
WO2013036546A2 (en) 2011-09-07 2013-03-14 Dow Corning Corporation Titanium containing complex and condensation reaction catalysts, methods for preparing the catalysts, and compositions containing the catalysts
US9139699B2 (en) 2012-10-04 2015-09-22 Dow Corning Corporation Metal containing condensation reaction catalysts, methods for preparing the catalysts, and compositions containing the catalysts
CN111362885A (zh) * 2020-03-06 2020-07-03 华东理工大学 一种苯并噻唑环取代的氨基酚氧基锌络合物及其制备方法和应用
RU2748114C1 (ru) * 2020-09-11 2021-05-19 Публичное акционерное общество "Нефтяная компания "Роснефть" (ПАО "НК "Роснефть") Способ получения прекатализатора { 2,4-ди-трет-бутил-6-[(трет-бутилимино)метил]фенолят} оксодихлорида ванадия(V) для синтеза этилен-пропиленовых каучуков СКЭПТ/СКЭП

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000030864A (ja) * 1998-07-14 2000-01-28 Minolta Co Ltd 有機エレクトロルミネセンス素子
WO2000037512A2 (en) * 1998-12-18 2000-06-29 Univation Technologies, Llc Olefin polymerization catalysts, their production and use
JP2001271063A (ja) * 2000-03-27 2001-10-02 Toyo Ink Mfg Co Ltd 有機エレクトロルミネッセンス素子用材料およびそれを使用した有機エレクトロルミネッセンス素子
WO2002006358A1 (en) * 2000-07-17 2002-01-24 Univation Technologies, Llc A catalyst system and its use in a polymerization process
WO2002046250A2 (en) * 2000-12-04 2002-06-13 Univation Technologies, Llc Catalyst composition, method of polymerization and polymer therefrom
US20030165711A1 (en) * 1998-06-23 2003-09-04 Youngkyoo Kim Novel organometallic luminescent materials and organic electroluminescent device containing same
WO2006036748A2 (en) * 2004-09-22 2006-04-06 Symyx Technologies, Inc. Heterocycle-amine ligands, compositions, complexes, and catalysts, and methods of making and using the same

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297465A (en) * 1980-10-29 1981-10-27 Eastman Kodak Company Catalysts for polymerizing propylene in a high temperature solution process
IL85097A (en) 1987-01-30 1992-02-16 Exxon Chemical Patents Inc Catalysts based on derivatives of a bis(cyclopentadienyl)group ivb metal compound,their preparation and their use in polymerization processes
US5384299A (en) * 1987-01-30 1995-01-24 Exxon Chemical Patents Inc. Ionic metallocene catalyst compositions
US5153157A (en) * 1987-01-30 1992-10-06 Exxon Chemical Patents Inc. Catalyst system of enhanced productivity
ZA882999B (en) 1987-05-04 1988-11-01 Shell Oil Company Preparation of olefin polymerization catalyst component
US5093415A (en) * 1987-05-19 1992-03-03 Union Carbide Chemicals & Plastics Technology Corporation Process for producing stereoregular polymers having a narrow molecular weight distribution
US4971936A (en) * 1989-07-10 1990-11-20 Shell Oil Company Catalyst component for making primarily isotactic elastomeric polypropylene or polybutene
US5064802A (en) * 1989-09-14 1991-11-12 The Dow Chemical Company Metal complex compounds
ES2085000T3 (es) * 1990-12-27 1996-05-16 Exxon Chemical Patents Inc Un compuesto de amido-metal de transicion y un sistema catalitico para la produccion de polipropileno isotactico.
JPH04272907A (ja) * 1991-02-27 1992-09-29 Mitsubishi Petrochem Co Ltd オレフィン重合体の製造法
KR100262023B1 (ko) * 1992-01-06 2000-07-15 그레이스 스티븐 에스. 개선된 촉매 조성물
CA2121721C (en) 1993-04-29 2004-11-23 Giampiero Morini Crystalline propylene polymers having high melt flow rate values and a narrow molecular weight distribution
TW354792B (en) * 1993-08-13 1999-03-21 Mitsui Petrochemical Ind Olefin polymerization catalyst and process for preparing polypropylene and propylene block copolymer
US5527929A (en) 1994-08-02 1996-06-18 The Dow Chemical Company Zwitterionic biscyclopentadienyl complexes
US6030917A (en) * 1996-07-23 2000-02-29 Symyx Technologies, Inc. Combinatorial synthesis and analysis of organometallic compounds and catalysts
US5985356A (en) * 1994-10-18 1999-11-16 The Regents Of The University Of California Combinatorial synthesis of novel materials
US5637660A (en) * 1995-04-17 1997-06-10 Lyondell Petrochemical Company Polymerization of α-olefins with transition metal catalysts based on bidentate ligands containing pyridine or quinoline moiety
JP3653825B2 (ja) * 1995-10-23 2005-06-02 東洋インキ製造株式会社 有機エレクトロルミネッセンス素子材料およびそれを使用した有機エレクトロルミネッセンス素子
JPH11514012A (ja) 1996-07-23 1999-11-30 サイミックス・テクノロジーズ 有機金属化合物及び触媒の組み合わせ合成並びに分析
US6720186B1 (en) * 1998-04-03 2004-04-13 Symyx Technologies, Inc. Method of research for creating and testing novel catalysts, reactions and polymers
TWI246520B (en) * 1997-04-25 2006-01-01 Mitsui Chemicals Inc Processes for olefin polymerization
IL122115A (en) 1997-07-27 2007-06-17 Technion Res & Dev Foundation Alpha polymerization method - olefins and polymers, copolymers and elastomers prepared by this method
EP1000069B1 (en) 1997-08-01 2003-03-12 Dow Global Technologies Inc. Catalyst activator
EP0938509B1 (en) * 1997-09-03 2002-11-20 Basell Poliolefine Italia S.p.A. Components and catalysts for the polymerization of olefins
JP4722287B2 (ja) 1998-02-20 2011-07-13 ダウ グローバル テクノロジーズ インコーポレーテッド 拡大したアニオンを含む触媒活性化剤
US6410660B1 (en) * 1998-03-27 2002-06-25 E. I. Du Pont De Nemours And Company Polymerization of olefins
US6175409B1 (en) * 1999-04-02 2001-01-16 Symyx Technologies, Inc. Flow-injection analysis and variable-flow light-scattering methods and apparatus for characterizing polymers
US6294388B1 (en) * 1998-04-03 2001-09-25 Symyx Technologies, Inc. Indirect calibration of polymer characterization systems
US6260407B1 (en) * 1998-04-03 2001-07-17 Symyx Technologies, Inc. High-temperature characterization of polymers
US6406632B1 (en) * 1998-04-03 2002-06-18 Symyx Technologies, Inc. Rapid characterization of polymers
KR100342541B1 (ko) 1998-04-16 2002-06-28 나까니시 히로유끼 올레핀 중합촉매 및 중합방법
US6306658B1 (en) * 1998-08-13 2001-10-23 Symyx Technologies Parallel reactor with internal sensing
US6759014B2 (en) * 2001-01-26 2004-07-06 Symyx Technologies, Inc. Apparatus and methods for parallel processing of multiple reaction mixtures
US6455316B1 (en) * 1998-08-13 2002-09-24 Symyx Technologies, Inc. Parallel reactor with internal sensing and method of using same
DE69900946T2 (de) 1998-10-19 2002-06-27 Symyx Technologies Inc Entwurf von kombinatorischen materialbibliotheken
JP4221129B2 (ja) * 1999-02-15 2009-02-12 富士フイルム株式会社 含窒素ヘテロ環化合物、有機発光素子材料、有機発光素子
JP4045684B2 (ja) * 1999-03-01 2008-02-13 コニカミノルタホールディングス株式会社 有機エレクトロルミネセンス素子
US6436292B1 (en) * 1999-04-02 2002-08-20 Symyx Technologies, Inc. Parallel high-performance liquid chromatography with post-separation treatment
US6296771B1 (en) * 1999-04-02 2001-10-02 Symyx Technologies, Inc. Parallel high-performance liquid chromatography with serial injection
US6507945B1 (en) * 1999-05-05 2003-01-14 Symyx Technologies, Inc. Synthesizing combinatorial libraries of materials
JP2001040346A (ja) * 1999-07-30 2001-02-13 Fuji Photo Film Co Ltd 発光素子材料およびそれを使用した発光素子
JP3938263B2 (ja) * 1999-11-09 2007-06-27 独立行政法人科学技術振興機構 金属錯体の製造方法
US7078164B1 (en) 2000-06-19 2006-07-18 Symyx Technologies, Inc. High throughput screen for identifying polymerization catalysts from potential catalysts
US7018589B1 (en) * 2000-07-19 2006-03-28 Symyx Technologies, Inc. High pressure parallel reactor
WO2002046249A2 (en) 2000-11-07 2002-06-13 Symyx Technologies, Inc. Methods of copolymerizing ethylene and isobutylene and polymers made thereby
GB0028317D0 (en) * 2000-11-21 2001-01-03 South Bank Univ Entpr Ltd Electroluminescent device incorporating polyaniline
JP3949391B2 (ja) * 2001-05-14 2007-07-25 富士フイルム株式会社 発光素子
SG147306A1 (en) 2001-11-06 2008-11-28 Dow Global Technologies Inc Isotactic propylene copolymers, their preparation and use
AU2003221701A1 (en) * 2002-04-12 2003-10-27 Dow Global Technologies Inc. Low molecular weight copolymer of ethylene and vinyl aromatic monomer and uses thereof
US6794514B2 (en) * 2002-04-12 2004-09-21 Symyx Technologies, Inc. Ethylene-styrene copolymers and phenol-triazole type complexes, catalysts, and processes for polymerizing
AU2003225156A1 (en) 2002-04-24 2003-11-10 Symyx Technologies, Inc. Bridged bi-aromatic ligands, complexes, catalysts and processes for polymerizing and poymers therefrom
US7160513B2 (en) 2002-12-20 2007-01-09 Symyx Technologies, Inc. Batch reactor with injection system
DE10309837A1 (de) 2003-03-05 2004-09-16 Basf Ag Katalysatoren für die Polymerisation von Styrol

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030165711A1 (en) * 1998-06-23 2003-09-04 Youngkyoo Kim Novel organometallic luminescent materials and organic electroluminescent device containing same
JP2000030864A (ja) * 1998-07-14 2000-01-28 Minolta Co Ltd 有機エレクトロルミネセンス素子
WO2000037512A2 (en) * 1998-12-18 2000-06-29 Univation Technologies, Llc Olefin polymerization catalysts, their production and use
JP2001271063A (ja) * 2000-03-27 2001-10-02 Toyo Ink Mfg Co Ltd 有機エレクトロルミネッセンス素子用材料およびそれを使用した有機エレクトロルミネッセンス素子
WO2002006358A1 (en) * 2000-07-17 2002-01-24 Univation Technologies, Llc A catalyst system and its use in a polymerization process
WO2002046250A2 (en) * 2000-12-04 2002-06-13 Univation Technologies, Llc Catalyst composition, method of polymerization and polymer therefrom
WO2006036748A2 (en) * 2004-09-22 2006-04-06 Symyx Technologies, Inc. Heterocycle-amine ligands, compositions, complexes, and catalysts, and methods of making and using the same

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
ANTHONY K ET AL: "Solid-state fluorescent photophysics of some 2-substituted benzothiazoles" JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 2, no. 12, 1984, pages 2111-2117, XP009011528 ISSN: 1472-779X *
BACH T ET AL: "Synthesis of 2-(o-hydroxyaryl)-4-arylthiazoles by regioselective Pd(0)-catalyzed cross-coupling" TETRAHEDRON LETTERS, vol. 41, no. 11, March 2000 (2000-03), pages 1707-1710, XP004202254 ISSN: 0040-4039 *
BEHER J ET AL: "O- und N-alkylsubstituierte 2-(2'-hydroxyphenyl)- benzimidazole und -1,3,4-oxadiazole als Komplexbildner und Extractionsmittel f}r Kupfer-II-ionen - O- and N-alkyl substituted 2-(2'-hydroxyphenyl)- benzimidazoles and -1,3,4-oxadiazoles and their use as complexants and extractants for copper(II) ions" JOURNAL F]R PRAKTISCHE CHEMIE, vol. 325, no. 5, 1983, pages 708-718, XP009066580 *
BENISVY L ET AL: "A phenol-imidazole pro-ligand that can exist as a phenoxyl radical, alone and when complexed to copper (II) and zinc (II)" DALTON TRANSACTIONS, no. 10, 2003, pages 1975-1985, XP002382183 *
CALHORDA M J ET AL: "Bis(eta-cyclopentadienyl)molybdenum (and -tungsten or -titanium) complexes with chelate imidazole derivatives and realted ligands" JOURNAL OF THE CHEMICAL SOCIETY, DALTON TRANSACTIONS, no. 8, 1980, pages 1443-1447, XP009066562 ISSN: 0300-9246 *
CARVALHO C ET AL: "Excited-state acidity of bifunctional compounds. Part 5. 5-(2- hydroxyphenyl)-3-phenyl-1,2,4-oxadiazole and 3-(2-hydroxyphenyl)-5-phenyl-1,2,4- oxadiazole" JOURNAL OF THE CHEMICAL SOCIETY, FARADAY TRANSACTIONS, vol. 93, no. 18, 21 September 1997 (1997-09-21), pages 3325-3329, XP000697790 ISSN: 0956-5000 *
COOK A H ET AL: "Experiments in the triazine and the glyoxaline series" JOURNAL OF THE CHEMICAL SOCIETY, 1941, pages 278-282, XP009017853 ISSN: 0368-1769 *
COUSIN ET AL: "Sur les nitriles salicyliques - Salicic nitriles" BULLETIN DE LA SOCIETE CHIMIQUE DE FRANCE, vol. 4, no. 15, 1914, pages 414-421, XP009066572 *
COZZI P G ET AL: "Oxazoline early transition metal complexes: functionalisable achiral titanium(IV), titanium(III), zirconium(IV), vanadium(III) and chiral zriconium (IV) bis(oxazoline) complexes" INORGANIC CHEMISTRY, vol. 34, no. 11, 24 May 1995 (1995-05-24), pages 2921-2930, XP002382175 ISSN: 0022-1669 *
COZZI P G ET AL: "(Hydroxyphenyl)oxazoline: a novel and remarkably facile entry into the area of chiral cationic alkylzirconium complexes which serve as polymerization catalysts" ORGANOMETALLICS, vol. 14, no. 11, 1995, pages 4994-4996, XP000909157 ISSN: 0276-7333 *
COZZI P G ET AL: "Bis(hydroxyphenyloxazolinato)-titanium(IV ) and -zirconium(IV) triflates as novel transition metal-base Lewis acids" JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, no. 20, 1995, pages 2557-2563, XP009066567 *
DELIWALA C V ET AL: "Chemotherapy of tuberculosis. Part III. Preparation of 5:5'dichlorosalicil and heterocyclic derivatives from dichlorosalicil and related alpha-diketones" PROCEEDINGS OF THE INDIAN ACADEMY OF SCIENCES, SECTION A, vol. 31, 1950, pages 107-116, XP009066816 *
FUKATA G ET AL: "Cyclodienones. 9. Reaction of 4-halo-2,4,6-tri-tert-butyl-2,5-cyclohexad ien-1-ones with pyrazoles and preparation of 1-(2-hydroxyphenyl)- and 1-(4-hydroxyphenyl)pyrazoles" HETEROCYCLES, vol. 19, no. 8, 1982, pages 1487-1495, XP009066593 *
MAURYA M R ET AL: "Oxo, dioxo and oxoperoxo complexes of molybdenum and tungsten with 2-(2-hydroxyphenyl)benzimidazole" JOURNAL OF CHEMICAL RESEARCH (SYNOPSES), no. 8, 1996, pages 390-391, XP009066565 *
MISHRA A ET AL: "Rare earth complexes with N,O-donor ligands - part I. Nitrato-complexes of terpositive yttrium and lighter lanthanides with 2-(2'-hydroxyphenyl) benzimidazole" JOURNAL OF THE INDIAN CHEMICAL SOCIETY, vol. 57, no. 3, March 1980 (1980-03), pages 249-251, XP009066564 ISSN: 0019-4522 *
MISHRA A ET AL: "Rare earth complexes with N,O-donor ligands - part II. Complexes of Gd(III), Tb(III), Dy(III) and Ho(III) with 2-(2'-hydroxyphenyl) benzimidazole" JOURNAL OF THE INDIAN CHEMICAL SOCIETY, vol. 58, no. 12, December 1981 (1981-12), pages 1197-1198, XP009066563 ISSN: 0019-4522 *
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 04, 31 August 2000 (2000-08-31) -& JP 2000 030864 A (MINOLTA CO LTD), 28 January 2000 (2000-01-28) *
PATENT ABSTRACTS OF JAPAN vol. 2002, no. 02, 2 April 2002 (2002-04-02) -& JP 2001 271063 A (TOYO INK MFG CO LTD), 2 October 2001 (2001-10-02) *
PLA-DALMAU A: "2-(2'-hydroxyphenyl)benzothiazoles, -benzoxazoles, and -benzimidazoles for plastic scintillation applications" JOURNAL OF ORGANIC CHEMISTRY, vol. 60, no. 17, 25 September 1995 (1995-09-25), pages 5468-5473, XP002382177 ISSN: 0022-3263 *
RYABUKHIN Y A ET AL: "Synthesis of bis(o-hydroxyphenyl)-1,3,5-triazines, 1,2,4-triazoles, and oxadiazole by recyclisation of the o-hydroxyphenyl-4-oxo-1,3-benzoxazinium cation" CHEMISTRY OF HETEROCYCLIC COMPOUNDS, vol. 19, no. 3, 1983, pages 332-336, XP009066578 ISSN: 0009-3122 *
RYABUKHIN Y I ET AL: "Synthesis and study of the structure of o-hydroxy-1,2,4-oxadiazoles" CHEMISTRY OF HETEROCYCLIC COMPOUNDS, vol. 28, no. 4, 1992, pages 454-463, XP009066577 *
WEIDNER-WELLS M A ET AL: "Amidino benzimidazole inhibitors of bacterial two-component systems." BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 11, no. 12, 18 June 2001 (2001-06-18), pages 1545-1548, XP002382176 ISSN: 0960-894X *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834039B2 (en) 2006-12-15 2010-11-16 Abbott Laboratories Oxadiazole compounds
WO2008076589A1 (en) 2006-12-20 2008-06-26 Exxonmobil Chemical Patents Inc. Phase separator and monomer recycle for supercritical polymerization process
WO2010132811A1 (en) * 2009-05-14 2010-11-18 Univation Technologies, Llc Mixed metal catalyst systems having a tailored hydrogen response
CN102414228A (zh) * 2009-05-14 2012-04-11 尤尼威蒂恩技术有限责任公司 具有特制的氢响应的混合金属催化剂体系
US8435914B2 (en) 2009-05-14 2013-05-07 Univation Technologies, Llc Mixed metal catalyst systems having a tailored hydrogen response
CN102414228B (zh) * 2009-05-14 2014-05-07 尤尼威蒂恩技术有限责任公司 具有特制的氢响应的混合金属催化剂体系
JP2021522243A (ja) * 2018-04-26 2021-08-30 エクソンモービル ケミカル パテンツ インコーポレイテッド 長鎖アルキル基を有するカチオンを含有する非配位性アニオン型活性化剤
US11414436B2 (en) 2018-04-26 2022-08-16 Exxonmobil Chemical Patents Inc. Non-coordinating anion type activators containing cation having large alkyl groups
WO2021242800A1 (en) 2020-05-29 2021-12-02 Dow Global Technologies Llc Attenuated post-metallocene catalysts
WO2021242801A1 (en) 2020-05-29 2021-12-02 Dow Global Technologies Llc Attenuated hybrid catalysts

Also Published As

Publication number Publication date
WO2006066126A3 (en) 2006-08-24
US7705157B2 (en) 2010-04-27
US20100048841A1 (en) 2010-02-25
US20060135713A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
US7705157B2 (en) Phenol-heterocyclic ligands, metal complexes, and their uses as catalysts
US10815318B2 (en) Quinolinyldiamido transition metal complexes, production and use thereof
EP1751169B1 (en) Bridged bi-aromatic catalysts, complexes, and method of using the same
US7157400B2 (en) Titanium substituted pyridyl amine complexes, catalysts and processes for polymerizing ethylene and stryene
EP2310399B1 (en) Pyridyldiamido transition metal complexes, production and use thereof
US6727361B2 (en) Phosphino substituted pyridine amine ligands
US20060025548A1 (en) Bridged bi-aromatic catalysts, complexes, and methods of using the same
EP2359930A1 (en) A polymer prepared in the presence of metal complexes bearing a polydentate heteroatom ligand
EP1501840A1 (en) Bridged bi-aromatic ligands, complexes, catalysts and processes for polymerizing and polymers therefrom
WO2018005201A1 (en) Quinolinyldiamido transition metal complexes, production and use thereof
WO2007076231A2 (en) Bridged phenol-heterocyclic ligands, metal complexes, and their uses as catalysts
WO2003087177A2 (en) Ethylene-styrene copolymers, complexes and catalysts with phenol-triazole ligands and processes for polymerizing therewith
US20090286944A1 (en) Select phenol-heterocycle ligands, metal complexes formed therefrom, and their uses as catalysts
EP1272537A2 (en) Ether-amine based polymerization catalysts, compositions and processes using same
EP3478694B9 (en) Quinolinyldiamido transition metal complexes, production and use thereof
EP1997834A1 (en) Catalysts
EP1364974A2 (en) Substituted pyridyl amine ligands, complexes, catalysts and processes for polymerizing and polymers
EP3068810B1 (en) Pyridyldiamido transition metal complexes, production and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005854472

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2005854472

Country of ref document: EP

122 Ep: pct application non-entry in european phase

Ref document number: 05854472

Country of ref document: EP

Kind code of ref document: A2